Network meta-analysis

Discontinuation due to adverse events

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

110

Randomized trials

Treatments

71,478

Participants

4,561

Events

In plain language

Across 110 trials with 71,478 participants, 3 of 46 treatments had a clearly better result than placebo on discontinuation due to adverse events, 13 a clearly worse one, and for 30 the evidence could not tell them apart from placebo. The most favorable estimate was for Mazdutide injection: hazard ratio (from event counts) 0.17 (95% credible interval 0.00 to 3.95).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Mazdutide injection MAZD_SC	0.17 (0.00 to 3.95)	0.00 to 4.27	Unclear
Premixed insulin INS_PREMIX	0.18 (0.02 to 0.96)	0.02 to 1.09	Better
Insulin degludec INS_DEGLUDEC	0.30 (0.10 to 0.86)	0.09 to 1.03	Better
Insulin aspart (prandial) INS_ASPART	0.42 (0.13 to 1.21)	0.12 to 1.48	Unclear
Macupatide OTHER_ACTIVE_macupatide	0.44 (0.01 to 17.39)	0.01 to 17.21	Unclear
Insulin glargine INS_GLARGINE	0.49 (0.30 to 0.74)	0.21 to 1.00	Better
Insulin detemir INS_DETEMIR	0.53 (0.15 to 1.77)	0.12 to 2.05	Unclear
Glimepiride GLIMEPIRIDE	0.58 (0.12 to 2.15)	0.11 to 2.55	Unclear
Insulin degludec with liraglutide injection IDEGLIRA_SC	0.61 (0.14 to 3.07)	0.13 to 3.49	Unclear
Standard care or no added treatment STANDARD_CARE	0.62 (0.01 to 60.54)	0.01 to 60.84	Unclear
Linagliptin LINAGLIPTIN	0.63 (0.01 to 49.15)	0.01 to 49.46	Unclear
Liraglutide and metformin injection LIRAMETF_SC	0.64 (0.01 to 47.82)	0.01 to 49.01	Unclear
Vildagliptin VILDAGLIPTIN	0.67 (0.01 to 56.02)	0.01 to 58.27	Unclear
Sitagliptin SITAGLIPTIN	0.68 (0.45 to 1.00)	0.31 to 1.42	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.81 (0.22 to 2.58)	0.19 to 2.99	Unclear
Insulin glargine with lixisenatide injection IGLARLIXI_SC	0.83 (0.43 to 1.58)	0.33 to 2.03	Unclear
Insulin lispro (prandial) INS_LISPRO	0.86 (0.44 to 1.78)	0.34 to 2.29	Unclear
Polyethylene glycol loxenatide injection PEGLOX_SC	0.92 (0.22 to 3.99)	0.20 to 4.37	Unclear
Efsubaglutide alfa injection EFSUBA_SC	0.95 (0.12 to 7.07)	0.11 to 7.64	Unclear
Investigator choice oral drug OTHER_ACTIVE_investigator_choice_oral_drug	1.00 (0.43 to 2.22)	0.34 to 2.71	Unclear
Metformin METFORMIN	1.29 (0.42 to 3.89)	0.35 to 4.62	Unclear
Exenatide extended release injection EXENER_SC	1.33 (0.83 to 2.08)	0.60 to 2.88	Unclear
Dapagliflozin DAPAGLIFLOZIN	1.36 (0.24 to 8.37)	0.21 to 9.11	Unclear
Dulaglutide injection DULA_SC	1.45 (0.95 to 2.19)	0.68 to 3.08	Unclear
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	1.55 (0.10 to 14.96)	0.10 to 16.58	Unclear
Ecnoglutide injection ECNO_SC	1.56 (0.07 to 62.14)	0.06 to 65.30	Unclear
Albiglutide injection ALBI_SC	1.60 (1.04 to 2.80)	0.74 to 3.73	Worse
Tirzepatide injection TIRZ_SC	1.63 (1.05 to 2.64)	0.77 to 3.70	Worse
Pioglitazone PIOGLITAZONE	1.72 (0.47 to 5.73)	0.39 to 6.47	Unclear
Semaglutide tablet SEMA_PO	1.78 (1.20 to 2.60)	0.82 to 3.67	Worse
Insulin icodec with semaglutide injection ICOSEMA_SC	1.93 (0.59 to 6.26)	0.51 to 7.05	Unclear
Liraglutide injection LIRA_SC	1.96 (1.33 to 2.79)	0.93 to 4.05	Worse
Lixisenatide injection LIXI_SC	2.23 (1.41 to 3.41)	1.00 to 4.75	Worse
Exenatide injection EXEN_SC	2.26 (1.22 to 3.93)	0.93 to 5.16	Worse
Semaglutide injection SEMA_SC	2.31 (1.64 to 3.42)	1.12 to 5.05	Worse
Visepegenatide injection VISEPE_SC	2.47 (0.36 to 23.92)	0.31 to 25.33	Unclear
Danuglipron tablet DANU_PO	2.60 (0.99 to 7.70)	0.82 to 9.07	Unclear
Efpe sc EFPE_SC	3.34 (1.39 to 8.80)	1.14 to 10.45	Worse
Bgm050 sc BGM050_SC	3.42 (0.14 to 119)	0.13 to 124	Unclear
Taspoglutide injection TASP_SC	3.62 (1.76 to 7.47)	1.37 to 9.39	Worse
Safiglipron (HRS-7535) tablet SAFIGL_PO	4.78 (1.17 to 28.92)	1.01 to 31.21	Worse
Loti po LOTI_PO	5.70 (2.50 to 14.14)	2.01 to 16.87	Worse
Liraglutide after insulin degludec injection LIRAGL_SC	5.91 (1.30 to 34.63)	1.13 to 39.31	Worse
HRS-7535 tablet HRS7535_PO	5.93 (0.54 to 157)	0.50 to 165	Unclear
Cotadutide injection COTA_SC	7.10 (2.94 to 17.63)	2.33 to 21.26	Worse
Dulaglutide with macupatide injection DULAMACU_SC	9.37 (0.60 to 233)	0.52 to 227	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	MAZD_SC	INS_PREMIX	INS_DEGLUDEC	INS_ASPART	OTHER_ACTIVE_macupatide	INS_GLARGINE	INS_DETEMIR	GLIMEPIRIDE	IDEGLIRA_SC	STANDARD_CARE	LINAGLIPTIN	LIRAMETF_SC	VILDAGLIPTIN	SITAGLIPTIN	OTHER_ACTIVE_additional_OAD	IGLARLIXI_SC	INS_LISPRO	PEGLOX_SC	EFSUBA_SC	OTHER_ACTIVE_investigator_choice_oral_drug	METFORMIN	EXENER_SC	DAPAGLIFLOZIN	DULA_SC	OTHER_ACTIVE_basal_bolus_insulin	ECNO_SC	ALBI_SC	TIRZ_SC	PIOGLITAZONE	SEMA_PO	ICOSEMA_SC	LIRA_SC	LIXI_SC	EXEN_SC	SEMA_SC	VISEPE_SC	DANU_PO	EFPE_SC	BGM050_SC	TASP_SC	SAFIGL_PO	LOTI_PO	LIRAGL_SC	HRS7535_PO	COTA_SC	DULAMACU_SC
PLACEBO	PLACEBO	6.05 0.25 to 314	5.54 1.04 to 58.03	3.34 1.16 to 9.59	2.37 0.83 to 7.54	2.26 0.06 to 173	2.04 1.35 to 3.37	1.90 0.56 to 6.86	1.73 0.47 to 8.15	1.64 0.33 to 7.11	1.60 0.02 to 180	1.59 0.02 to 146	1.55 0.02 to 165	1.49 0.02 to 182	1.47 1.00 to 2.23	1.23 0.39 to 4.47	1.21 0.63 to 2.35	1.16 0.56 to 2.26	1.09 0.25 to 4.48	1.05 0.14 to 8.27	1.00 0.45 to 2.32	0.78 0.26 to 2.36	0.75 0.48 to 1.21	0.74 0.12 to 4.25	0.69 0.46 to 1.06	0.65 0.07 to 9.84	0.64 0.02 to 15.16	0.63 0.36 to 0.96	0.61 0.38 to 0.95	0.58 0.17 to 2.15	0.56 0.38 to 0.83	0.52 0.16 to 1.69	0.51 0.36 to 0.75	0.45 0.29 to 0.71	0.44 0.25 to 0.82	0.43 0.29 to 0.61	0.40 0.04 to 2.77	0.38 0.13 to 1.01	0.30 0.11 to 0.72	0.29 0.01 to 7.33	0.28 0.13 to 0.57	0.21 0.03 to 0.86	0.18 0.07 to 0.40	0.17 0.03 to 0.77	0.17 0.01 to 1.86	0.14 0.06 to 0.34	0.11 0.00 to 1.65
MAZD_SC	0.17 0.00 to 3.95	MAZD_SC	0.96 0.01 to 44.61	0.55 0.01 to 15.99	0.39 0.01 to 11.56	0.37 0.00 to 85.61	0.34 0.01 to 8.62	0.31 0.01 to 10.11	0.29 0.00 to 9.53	0.26 0.00 to 9.09	0.26 0.00 to 86.41	0.25 0.00 to 78.22	0.25 0.00 to 69.05	0.23 0.00 to 82.39	0.25 0.00 to 6.10	0.20 0.00 to 6.35	0.20 0.00 to 5.11	0.19 0.00 to 4.97	0.18 0.00 to 5.79	0.17 0.00 to 7.63	0.16 0.00 to 4.44	0.13 0.00 to 3.52	0.13 0.00 to 3.06	0.12 0.00 to 4.33	0.12 0.00 to 2.80	0.11 0.00 to 7.19	0.10 0.00 to 9.34	0.10 0.00 to 2.67	0.10 0.00 to 2.51	0.10 0.00 to 3.12	0.09 0.00 to 2.42	0.09 0.00 to 2.67	0.08 0.00 to 2.11	0.07 0.00 to 1.89	0.08 0.00 to 1.88	0.07 0.00 to 1.77	0.06 0.00 to 2.84	0.06 0.00 to 1.80	0.05 0.00 to 1.32	0.04 0.00 to 4.48	0.05 0.00 to 1.23	0.03 0.00 to 1.14	0.03 0.00 to 0.77	0.03 0.00 to 0.97	0.02 0.00 to 1.62	0.02 0.00 to 0.64	0.02 0.00 to 1.32
INS_PREMIX	0.18 0.02 to 0.96	1.04 0.02 to 73.47	INS_PREMIX	0.60 0.05 to 4.53	0.42 0.03 to 3.37	0.39 0.01 to 39.59	0.37 0.03 to 2.06	0.34 0.03 to 2.84	0.30 0.02 to 3.02	0.29 0.02 to 2.82	0.27 0.00 to 43.69	0.25 0.00 to 42.30	0.26 0.00 to 38.31	0.25 0.00 to 39.47	0.26 0.02 to 1.47	0.22 0.02 to 1.92	0.22 0.02 to 1.31	0.21 0.02 to 1.23	0.19 0.01 to 1.77	0.18 0.01 to 2.81	0.18 0.02 to 1.18	0.14 0.01 to 1.09	0.13 0.01 to 0.75	0.13 0.01 to 1.49	0.13 0.01 to 0.70	0.11 0.00 to 3.03	0.11 0.00 to 4.39	0.11 0.01 to 0.63	0.11 0.01 to 0.62	0.10 0.01 to 0.92	0.10 0.01 to 0.56	0.09 0.01 to 0.73	0.09 0.01 to 0.52	0.08 0.01 to 0.44	0.08 0.01 to 0.41	0.08 0.01 to 0.43	0.07 0.00 to 0.92	0.07 0.01 to 0.50	0.05 0.00 to 0.37	0.05 0.00 to 1.89	0.05 0.00 to 0.30	0.04 0.00 to 0.34	0.03 0.00 to 0.21	0.03 0.00 to 0.29	0.03 0.00 to 0.58	0.02 0.00 to 0.17	0.02 0.00 to 0.49
INS_DEGLUDEC	0.30 0.10 to 0.86	1.80 0.06 to 99.96	1.67 0.22 to 21.73	INS_DEGLUDEC	0.71 0.16 to 3.48	0.68 0.01 to 56.28	0.61 0.22 to 1.85	0.57 0.12 to 2.97	0.52 0.10 to 3.31	0.49 0.09 to 2.34	0.48 0.00 to 64.61	0.47 0.01 to 48.53	0.46 0.01 to 55.30	0.45 0.00 to 59.58	0.44 0.15 to 1.38	0.37 0.08 to 1.91	0.36 0.11 to 1.23	0.34 0.11 to 1.10	0.32 0.06 to 1.98	0.31 0.03 to 3.14	0.30 0.08 to 1.10	0.23 0.05 to 1.07	0.22 0.07 to 0.69	0.22 0.03 to 1.67	0.21 0.07 to 0.61	0.19 0.02 to 3.87	0.19 0.00 to 5.64	0.19 0.06 to 0.55	0.18 0.07 to 0.47	0.18 0.04 to 0.91	0.17 0.06 to 0.52	0.16 0.03 to 0.77	0.15 0.05 to 0.47	0.13 0.04 to 0.41	0.13 0.04 to 0.44	0.13 0.04 to 0.39	0.12 0.01 to 1.11	0.11 0.03 to 0.49	0.09 0.02 to 0.35	0.09 0.00 to 2.50	0.08 0.02 to 0.31	0.06 0.01 to 0.36	0.05 0.01 to 0.20	0.05 0.01 to 0.32	0.05 0.00 to 0.69	0.04 0.01 to 0.17	0.03 0.00 to 0.63
INS_ASPART	0.42 0.13 to 1.21	2.55 0.09 to 135	2.36 0.30 to 30.60	1.41 0.29 to 6.13	INS_ASPART	0.96 0.02 to 75.56	0.86 0.26 to 2.75	0.79 0.15 to 4.23	0.73 0.13 to 4.74	0.69 0.10 to 4.29	0.66 0.01 to 88.72	0.64 0.01 to 70.95	0.66 0.01 to 74.17	0.61 0.01 to 85.23	0.62 0.19 to 1.87	0.52 0.11 to 2.63	0.51 0.14 to 1.81	0.49 0.13 to 1.69	0.45 0.07 to 2.71	0.44 0.04 to 4.31	0.42 0.10 to 1.63	0.33 0.07 to 1.54	0.32 0.09 to 0.99	0.30 0.03 to 2.30	0.29 0.09 to 0.89	0.27 0.02 to 5.08	0.26 0.01 to 7.52	0.26 0.07 to 0.80	0.26 0.07 to 0.80	0.25 0.05 to 1.35	0.24 0.07 to 0.73	0.22 0.05 to 1.00	0.22 0.07 to 0.65	0.19 0.06 to 0.59	0.19 0.05 to 0.63	0.18 0.06 to 0.48	0.17 0.01 to 1.60	0.16 0.03 to 0.66	0.12 0.03 to 0.49	0.12 0.00 to 3.47	0.12 0.03 to 0.41	0.08 0.01 to 0.51	0.07 0.02 to 0.28	0.07 0.01 to 0.45	0.07 0.00 to 0.97	0.06 0.01 to 0.23	0.04 0.00 to 0.91
OTHER_ACTIVE_macupatide	0.44 0.01 to 17.39	2.70 0.01 to 543	2.56 0.03 to 184	1.46 0.02 to 69.25	1.04 0.01 to 52.15	OTHER_ACTIVE_macupatide	0.93 0.01 to 37.74	0.87 0.01 to 45.27	0.78 0.01 to 40.07	0.72 0.01 to 38.81	0.68 0.00 to 308	0.65 0.00 to 281	0.70 0.00 to 246	0.62 0.00 to 261	0.66 0.01 to 25.59	0.56 0.01 to 25.64	0.54 0.01 to 21.56	0.51 0.01 to 20.90	0.49 0.00 to 23.67	0.44 0.00 to 33.21	0.44 0.01 to 18.69	0.35 0.00 to 16.44	0.34 0.00 to 13.64	0.32 0.00 to 19.67	0.31 0.00 to 12.26	0.28 0.00 to 30.54	0.27 0.00 to 36.60	0.27 0.00 to 11.39	0.27 0.00 to 11.02	0.26 0.00 to 12.58	0.25 0.00 to 9.71	0.23 0.00 to 10.61	0.23 0.00 to 8.88	0.20 0.00 to 7.99	0.20 0.00 to 8.26	0.19 0.00 to 7.62	0.17 0.00 to 11.16	0.17 0.00 to 8.00	0.13 0.00 to 5.93	0.12 0.00 to 16.48	0.12 0.00 to 5.20	0.09 0.00 to 4.66	0.08 0.00 to 3.43	0.07 0.00 to 4.32	0.07 0.00 to 6.16	0.06 0.00 to 2.72	0.05 0.00 to 2.43
INS_GLARGINE	0.49 0.30 to 0.74	2.90 0.12 to 156	2.71 0.49 to 28.82	1.63 0.54 to 4.64	1.16 0.36 to 3.87	1.08 0.03 to 86.37	INS_GLARGINE	0.92 0.27 to 3.43	0.84 0.21 to 3.92	0.80 0.16 to 3.33	0.79 0.01 to 89.07	0.77 0.01 to 72.01	0.76 0.01 to 80.62	0.73 0.01 to 87.83	0.72 0.41 to 1.22	0.60 0.17 to 2.32	0.59 0.31 to 1.09	0.57 0.25 to 1.13	0.53 0.12 to 2.25	0.51 0.07 to 4.09	0.49 0.19 to 1.17	0.38 0.12 to 1.19	0.37 0.21 to 0.62	0.36 0.05 to 2.18	0.34 0.20 to 0.53	0.31 0.03 to 5.00	0.31 0.01 to 7.89	0.31 0.15 to 0.53	0.30 0.17 to 0.47	0.29 0.08 to 1.09	0.28 0.15 to 0.47	0.25 0.07 to 0.85	0.25 0.14 to 0.42	0.22 0.12 to 0.36	0.22 0.12 to 0.39	0.21 0.11 to 0.34	0.20 0.02 to 1.44	0.19 0.06 to 0.53	0.15 0.05 to 0.38	0.14 0.00 to 3.70	0.14 0.06 to 0.29	0.10 0.02 to 0.43	0.09 0.03 to 0.21	0.08 0.01 to 0.39	0.08 0.00 to 0.93	0.07 0.02 to 0.18	0.05 0.00 to 0.85
INS_DETEMIR	0.53 0.15 to 1.77	3.20 0.10 to 190	2.95 0.35 to 38.04	1.77 0.34 to 8.67	1.26 0.24 to 6.73	1.16 0.02 to 105	1.08 0.29 to 3.77	INS_DETEMIR	0.91 0.14 to 6.62	0.85 0.12 to 5.65	0.84 0.01 to 106	0.83 0.01 to 88.89	0.83 0.01 to 90.93	0.78 0.01 to 105	0.78 0.21 to 2.66	0.65 0.12 to 3.65	0.64 0.15 to 2.43	0.61 0.14 to 2.38	0.57 0.08 to 3.74	0.56 0.05 to 5.94	0.52 0.12 to 2.19	0.41 0.08 to 2.07	0.40 0.12 to 1.22	0.39 0.04 to 3.24	0.36 0.09 to 1.29	0.33 0.02 to 6.57	0.33 0.01 to 9.73	0.32 0.08 to 1.17	0.32 0.08 to 1.12	0.31 0.06 to 1.78	0.30 0.08 to 1.03	0.27 0.05 to 1.45	0.27 0.07 to 0.92	0.24 0.06 to 0.83	0.23 0.06 to 0.82	0.23 0.06 to 0.77	0.21 0.02 to 2.02	0.20 0.04 to 0.98	0.16 0.03 to 0.71	0.15 0.00 to 4.73	0.14 0.03 to 0.60	0.11 0.01 to 0.71	0.09 0.02 to 0.39	0.09 0.01 to 0.60	0.09 0.00 to 1.26	0.07 0.02 to 0.33	0.05 0.00 to 1.19
GLIMEPIRIDE	0.58 0.12 to 2.15	3.44 0.10 to 216	3.28 0.33 to 48.15	1.93 0.30 to 10.21	1.37 0.21 to 7.89	1.29 0.02 to 117	1.19 0.26 to 4.70	1.10 0.15 to 7.12	GLIMEPIRIDE	0.94 0.11 to 6.60	0.92 0.01 to 125	0.92 0.01 to 98.84	0.89 0.01 to 108	0.83 0.01 to 110	0.85 0.17 to 3.37	0.70 0.10 to 4.42	0.70 0.13 to 2.97	0.67 0.13 to 2.95	0.62 0.08 to 4.49	0.60 0.05 to 7.03	0.58 0.10 to 2.77	0.45 0.07 to 2.53	0.44 0.09 to 1.72	0.42 0.04 to 3.81	0.40 0.09 to 1.42	0.37 0.02 to 7.63	0.35 0.01 to 11.88	0.36 0.07 to 1.43	0.35 0.07 to 1.38	0.34 0.05 to 2.21	0.33 0.07 to 1.29	0.30 0.05 to 1.80	0.30 0.06 to 1.16	0.26 0.05 to 1.04	0.26 0.05 to 1.08	0.25 0.05 to 0.96	0.23 0.01 to 2.60	0.22 0.03 to 1.13	0.17 0.03 to 0.86	0.16 0.00 to 5.27	0.16 0.03 to 0.71	0.12 0.01 to 0.86	0.10 0.02 to 0.48	0.10 0.01 to 0.76	0.09 0.00 to 1.60	0.08 0.01 to 0.40	0.06 0.00 to 1.28
IDEGLIRA_SC	0.61 0.14 to 3.07	3.91 0.11 to 228	3.49 0.35 to 52.30	2.02 0.43 to 10.80	1.45 0.23 to 10.47	1.39 0.03 to 138	1.25 0.30 to 6.14	1.17 0.18 to 8.52	1.06 0.15 to 8.87	IDEGLIRA_SC	1.00 0.01 to 132	1.00 0.01 to 122	0.95 0.01 to 122	0.91 0.01 to 133	0.90 0.20 to 4.60	0.75 0.12 to 5.53	0.74 0.16 to 3.91	0.70 0.14 to 3.87	0.67 0.08 to 5.23	0.64 0.06 to 8.18	0.61 0.11 to 3.58	0.48 0.08 to 3.27	0.46 0.10 to 2.36	0.44 0.04 to 4.61	0.42 0.09 to 2.18	0.40 0.03 to 9.36	0.39 0.01 to 13.56	0.38 0.08 to 1.98	0.37 0.08 to 1.87	0.36 0.05 to 2.81	0.34 0.08 to 1.77	0.32 0.05 to 2.30	0.31 0.07 to 1.63	0.27 0.06 to 1.43	0.27 0.06 to 1.46	0.26 0.06 to 1.34	0.24 0.02 to 2.88	0.23 0.04 to 1.58	0.18 0.03 to 1.21	0.18 0.00 to 6.36	0.17 0.03 to 0.98	0.12 0.01 to 1.07	0.10 0.02 to 0.64	0.10 0.01 to 0.93	0.10 0.00 to 1.72	0.08 0.02 to 0.53	0.06 0.00 to 1.52
STANDARD_CARE	0.62 0.01 to 60.54	3.91 0.01 to 1499	3.74 0.02 to 556	2.06 0.02 to 228	1.52 0.01 to 146	1.46 0.00 to 760	1.27 0.01 to 128	1.18 0.01 to 140	1.09 0.01 to 141	1.00 0.01 to 129	STANDARD_CARE	1.01 0.00 to 605	0.99 0.00 to 597	0.97 0.00 to 580	0.91 0.01 to 87.08	0.78 0.01 to 82.68	0.73 0.01 to 72.05	0.71 0.01 to 75.16	0.67 0.00 to 77.53	0.67 0.00 to 101	0.62 0.01 to 60.54	0.49 0.00 to 48.40	0.46 0.00 to 45.23	0.46 0.00 to 61.18	0.42 0.00 to 42.59	0.43 0.00 to 76.38	0.39 0.00 to 93.26	0.38 0.00 to 37.99	0.38 0.00 to 37.10	0.37 0.00 to 43.18	0.34 0.00 to 33.08	0.32 0.00 to 35.31	0.32 0.00 to 31.36	0.28 0.00 to 27.13	0.28 0.00 to 26.97	0.26 0.00 to 25.40	0.24 0.00 to 33.40	0.23 0.00 to 25.93	0.19 0.00 to 19.19	0.17 0.00 to 47.91	0.17 0.00 to 17.21	0.12 0.00 to 15.58	0.11 0.00 to 11.03	0.10 0.00 to 12.65	0.10 0.00 to 16.72	0.09 0.00 to 8.93	0.06 0.00 to 14.03
LINAGLIPTIN	0.63 0.01 to 49.15	4.02 0.01 to 1416	3.96 0.02 to 548	2.15 0.02 to 182	1.55 0.01 to 130	1.54 0.00 to 672	1.30 0.01 to 101	1.20 0.01 to 110	1.09 0.01 to 105	1.00 0.01 to 102	0.99 0.00 to 547	LINAGLIPTIN	0.98 0.00 to 478	0.97 0.00 to 555	0.92 0.01 to 72.36	0.81 0.01 to 67.72	0.76 0.01 to 63.65	0.73 0.01 to 56.38	0.70 0.01 to 69.21	0.66 0.00 to 81.21	0.64 0.01 to 54.29	0.50 0.00 to 43.61	0.47 0.01 to 37.92	0.46 0.00 to 50.21	0.44 0.00 to 32.87	0.41 0.00 to 76.65	0.39 0.00 to 94.31	0.39 0.00 to 29.99	0.39 0.00 to 30.53	0.37 0.00 to 36.27	0.35 0.00 to 27.69	0.33 0.00 to 28.24	0.32 0.00 to 25.81	0.28 0.00 to 23.11	0.28 0.00 to 22.35	0.27 0.00 to 21.22	0.25 0.00 to 29.90	0.24 0.00 to 22.30	0.19 0.00 to 15.71	0.18 0.00 to 38.83	0.18 0.00 to 14.24	0.12 0.00 to 12.66	0.11 0.00 to 9.41	0.10 0.00 to 10.28	0.10 0.00 to 18.16	0.09 0.00 to 7.74	0.06 0.00 to 11.73
LIRAMETF_SC	0.64 0.01 to 47.82	3.95 0.01 to 1283	3.83 0.03 to 494	2.15 0.02 to 186	1.52 0.01 to 132	1.43 0.00 to 614	1.32 0.01 to 104	1.21 0.01 to 108	1.13 0.01 to 108	1.05 0.01 to 94.66	1.01 0.00 to 584	1.02 0.00 to 457	LIRAMETF_SC	0.98 0.00 to 577	0.94 0.01 to 75.57	0.78 0.01 to 71.20	0.78 0.01 to 57.95	0.74 0.01 to 62.24	0.70 0.01 to 63.77	0.68 0.00 to 76.35	0.64 0.01 to 49.20	0.50 0.00 to 43.75	0.48 0.00 to 37.43	0.45 0.00 to 45.18	0.44 0.00 to 35.25	0.43 0.00 to 73.93	0.38 0.00 to 75.68	0.40 0.00 to 30.99	0.39 0.00 to 31.02	0.38 0.00 to 34.84	0.36 0.00 to 27.65	0.33 0.00 to 29.18	0.33 0.00 to 24.86	0.28 0.00 to 21.73	0.29 0.00 to 22.16	0.27 0.00 to 21.80	0.25 0.00 to 30.55	0.24 0.00 to 20.50	0.19 0.00 to 15.66	0.17 0.00 to 37.54	0.17 0.00 to 14.44	0.12 0.00 to 12.02	0.11 0.00 to 9.29	0.10 0.00 to 10.94	0.10 0.00 to 15.57	0.09 0.00 to 6.77	0.06 0.00 to 11.09
VILDAGLIPTIN	0.67 0.01 to 56.02	4.28 0.01 to 1490	3.93 0.03 to 553	2.22 0.02 to 200	1.65 0.01 to 144	1.62 0.00 to 614	1.38 0.01 to 117	1.29 0.01 to 122	1.20 0.01 to 114	1.10 0.01 to 115	1.03 0.00 to 659	1.03 0.00 to 638	1.02 0.00 to 627	VILDAGLIPTIN	0.98 0.01 to 82.83	0.84 0.01 to 72.78	0.82 0.01 to 69.96	0.76 0.01 to 65.51	0.71 0.00 to 77.70	0.70 0.00 to 94.76	0.67 0.01 to 55.82	0.52 0.00 to 49.76	0.51 0.00 to 41.87	0.47 0.00 to 54.97	0.46 0.00 to 38.63	0.44 0.00 to 78.70	0.38 0.00 to 109	0.41 0.00 to 33.75	0.40 0.00 to 32.66	0.39 0.00 to 36.01	0.38 0.00 to 33.75	0.35 0.00 to 32.89	0.34 0.00 to 28.47	0.31 0.00 to 25.44	0.30 0.00 to 24.67	0.29 0.00 to 24.61	0.27 0.00 to 34.97	0.25 0.00 to 23.30	0.20 0.00 to 18.05	0.19 0.00 to 43.41	0.18 0.00 to 15.91	0.13 0.00 to 13.83	0.12 0.00 to 10.12	0.11 0.00 to 11.37	0.10 0.00 to 16.24	0.10 0.00 to 8.00	0.07 0.00 to 11.63
SITAGLIPTIN	0.68 0.45 to 1.00	4.04 0.16 to 211	3.80 0.68 to 40.55	2.28 0.72 to 6.73	1.62 0.53 to 5.21	1.52 0.04 to 116	1.39 0.82 to 2.47	1.29 0.38 to 4.87	1.17 0.30 to 5.80	1.12 0.22 to 4.94	1.10 0.01 to 130	1.08 0.01 to 100	1.06 0.01 to 113	1.02 0.01 to 122	SITAGLIPTIN	0.84 0.25 to 3.11	0.83 0.39 to 1.70	0.79 0.35 to 1.65	0.74 0.17 to 3.22	0.72 0.09 to 5.86	0.68 0.30 to 1.58	0.53 0.17 to 1.66	0.51 0.30 to 0.87	0.50 0.08 to 2.98	0.47 0.27 to 0.81	0.44 0.05 to 6.73	0.43 0.01 to 10.70	0.43 0.21 to 0.74	0.42 0.22 to 0.73	0.40 0.12 to 1.48	0.39 0.25 to 0.58	0.36 0.11 to 1.18	0.35 0.22 to 0.53	0.31 0.18 to 0.53	0.30 0.16 to 0.59	0.29 0.18 to 0.44	0.27 0.03 to 2.01	0.26 0.08 to 0.73	0.20 0.07 to 0.54	0.19 0.01 to 5.03	0.19 0.09 to 0.37	0.14 0.02 to 0.63	0.12 0.04 to 0.28	0.11 0.02 to 0.53	0.11 0.00 to 1.24	0.10 0.04 to 0.24	0.07 0.00 to 1.21
OTHER_ACTIVE_additional_OAD	0.81 0.22 to 2.58	4.92 0.16 to 276	4.60 0.52 to 60.95	2.71 0.52 to 12.22	1.93 0.38 to 9.28	1.77 0.04 to 169	1.66 0.43 to 5.81	1.53 0.27 to 8.64	1.42 0.23 to 9.64	1.33 0.18 to 8.24	1.29 0.01 to 169	1.24 0.01 to 133	1.28 0.01 to 138	1.19 0.01 to 168	1.19 0.32 to 4.05	OTHER_ACTIVE_additional_OAD	0.98 0.24 to 3.73	0.94 0.22 to 3.58	0.87 0.13 to 5.46	0.84 0.08 to 8.45	0.81 0.18 to 3.36	0.64 0.12 to 3.27	0.61 0.16 to 2.08	0.60 0.06 to 4.77	0.56 0.14 to 1.93	0.51 0.04 to 9.65	0.50 0.01 to 15.12	0.50 0.13 to 1.70	0.50 0.13 to 1.67	0.48 0.08 to 2.62	0.46 0.12 to 1.53	0.42 0.08 to 2.16	0.41 0.11 to 1.38	0.36 0.09 to 1.29	0.35 0.09 to 1.37	0.35 0.10 to 1.03	0.32 0.02 to 3.22	0.31 0.06 to 1.43	0.24 0.05 to 1.08	0.23 0.01 to 7.46	0.22 0.05 to 0.88	0.17 0.02 to 1.08	0.14 0.03 to 0.60	0.13 0.02 to 0.91	0.14 0.00 to 1.92	0.11 0.02 to 0.50	0.08 0.00 to 1.76
IGLARLIXI_SC	0.83 0.43 to 1.58	4.94 0.20 to 258	4.57 0.76 to 48.60	2.76 0.82 to 9.07	1.95 0.55 to 7.38	1.84 0.05 to 145	1.69 0.92 to 3.24	1.56 0.41 to 6.59	1.43 0.34 to 7.74	1.35 0.26 to 6.43	1.36 0.01 to 145	1.31 0.02 to 129	1.29 0.02 to 142	1.21 0.01 to 154	1.21 0.59 to 2.54	1.02 0.27 to 4.15	IGLARLIXI_SC	0.96 0.37 to 2.24	0.90 0.18 to 4.23	0.88 0.10 to 7.57	0.82 0.30 to 2.31	0.65 0.18 to 2.30	0.62 0.29 to 1.28	0.61 0.08 to 3.97	0.57 0.27 to 1.17	0.53 0.05 to 8.97	0.53 0.01 to 13.69	0.51 0.23 to 1.07	0.51 0.23 to 1.03	0.49 0.12 to 2.07	0.46 0.22 to 0.97	0.43 0.11 to 1.59	0.42 0.20 to 0.87	0.37 0.20 to 0.67	0.37 0.17 to 0.79	0.35 0.17 to 0.71	0.33 0.03 to 2.59	0.31 0.09 to 1.00	0.24 0.08 to 0.74	0.24 0.01 to 6.54	0.23 0.09 to 0.60	0.17 0.03 to 0.80	0.14 0.05 to 0.40	0.14 0.02 to 0.72	0.14 0.01 to 1.68	0.12 0.04 to 0.34	0.09 0.00 to 1.46
INS_LISPRO	0.86 0.44 to 1.78	5.17 0.20 to 285	4.81 0.81 to 55.81	2.90 0.91 to 9.27	2.06 0.59 to 7.91	1.97 0.05 to 162	1.76 0.89 to 4.01	1.63 0.42 to 7.11	1.50 0.34 to 7.96	1.43 0.26 to 6.92	1.40 0.01 to 167	1.37 0.02 to 133	1.35 0.02 to 138	1.31 0.02 to 168	1.26 0.61 to 2.89	1.07 0.28 to 4.52	1.04 0.45 to 2.68	INS_LISPRO	0.95 0.19 to 4.73	0.90 0.11 to 8.09	0.85 0.32 to 2.63	0.67 0.19 to 2.46	0.65 0.30 to 1.46	0.64 0.09 to 4.32	0.59 0.29 to 1.29	0.55 0.05 to 9.18	0.55 0.01 to 15.24	0.54 0.26 to 1.10	0.53 0.28 to 1.01	0.50 0.13 to 2.21	0.48 0.23 to 1.08	0.45 0.12 to 1.80	0.44 0.21 to 0.97	0.39 0.18 to 0.89	0.38 0.18 to 0.89	0.37 0.18 to 0.79	0.35 0.03 to 2.72	0.33 0.09 to 1.14	0.26 0.08 to 0.79	0.25 0.01 to 7.05	0.24 0.09 to 0.65	0.18 0.03 to 0.88	0.15 0.05 to 0.45	0.14 0.02 to 0.78	0.15 0.01 to 1.72	0.12 0.04 to 0.38	0.09 0.00 to 1.59
PEGLOX_SC	0.92 0.22 to 3.99	5.61 0.17 to 336	5.26 0.57 to 78.70	3.08 0.50 to 17.94	2.21 0.37 to 14.44	2.05 0.04 to 211	1.88 0.44 to 8.59	1.76 0.27 to 12.50	1.63 0.22 to 13.19	1.49 0.19 to 11.82	1.49 0.01 to 218	1.42 0.01 to 171	1.43 0.02 to 195	1.41 0.01 to 202	1.36 0.31 to 6.04	1.16 0.18 to 7.78	1.12 0.24 to 5.62	1.05 0.21 to 5.30	PEGLOX_SC	0.97 0.08 to 12.07	0.92 0.19 to 4.70	0.72 0.20 to 2.80	0.69 0.16 to 3.13	0.69 0.09 to 4.99	0.63 0.15 to 2.89	0.59 0.04 to 13.38	0.58 0.01 to 19.06	0.57 0.13 to 2.65	0.56 0.13 to 2.57	0.54 0.10 to 3.40	0.51 0.12 to 2.33	0.49 0.08 to 2.94	0.47 0.11 to 2.09	0.41 0.09 to 2.00	0.41 0.09 to 1.94	0.39 0.09 to 1.78	0.36 0.03 to 4.50	0.35 0.06 to 2.03	0.27 0.05 to 1.55	0.26 0.01 to 9.19	0.26 0.05 to 1.27	0.19 0.02 to 1.20	0.16 0.03 to 0.87	0.15 0.02 to 1.26	0.15 0.00 to 2.60	0.13 0.02 to 0.70	0.10 0.00 to 2.12
EFSUBA_SC	0.95 0.12 to 7.07	5.83 0.13 to 465	5.55 0.36 to 114	3.21 0.32 to 30.20	2.27 0.23 to 23.71	2.27 0.03 to 266	1.96 0.24 to 15.12	1.79 0.17 to 18.72	1.67 0.14 to 19.95	1.57 0.12 to 17.70	1.50 0.01 to 269	1.52 0.01 to 216	1.48 0.01 to 220	1.42 0.01 to 270	1.38 0.17 to 11.06	1.19 0.12 to 12.13	1.14 0.13 to 9.57	1.11 0.12 to 9.00	1.03 0.08 to 12.06	EFSUBA_SC	0.95 0.11 to 8.72	0.74 0.07 to 6.99	0.72 0.09 to 5.45	0.70 0.04 to 9.75	0.65 0.08 to 5.12	0.63 0.03 to 20.51	0.60 0.01 to 24.51	0.59 0.07 to 4.63	0.58 0.07 to 4.60	0.56 0.05 to 6.33	0.54 0.07 to 4.16	0.49 0.05 to 5.21	0.49 0.06 to 3.77	0.43 0.05 to 3.36	0.42 0.05 to 3.43	0.41 0.05 to 3.05	0.38 0.02 to 5.91	0.36 0.04 to 3.47	0.29 0.03 to 2.54	0.27 0.00 to 11.87	0.26 0.03 to 2.24	0.19 0.01 to 2.32	0.16 0.02 to 1.48	0.16 0.01 to 2.01	0.15 0.00 to 3.82	0.13 0.01 to 1.20	0.10 0.00 to 3.23
OTHER_ACTIVE_investigator_choice_oral_drug	1.00 0.43 to 2.22	6.11 0.23 to 322	5.65 0.84 to 64.99	3.33 0.91 to 12.24	2.39 0.61 to 9.66	2.26 0.05 to 180	2.05 0.85 to 5.29	1.91 0.46 to 8.68	1.74 0.36 to 9.65	1.65 0.28 to 8.75	1.61 0.02 to 191	1.57 0.02 to 153	1.56 0.02 to 171	1.48 0.02 to 187	1.47 0.63 to 3.37	1.24 0.30 to 5.56	1.22 0.43 to 3.36	1.17 0.38 to 3.16	1.09 0.21 to 5.37	1.05 0.11 to 9.00	OTHER_ACTIVE_investigator_choice_oral_drug	0.78 0.20 to 3.07	0.75 0.31 to 1.80	0.73 0.10 to 5.01	0.70 0.28 to 1.68	0.64 0.06 to 10.53	0.63 0.01 to 16.68	0.63 0.23 to 1.48	0.62 0.23 to 1.49	0.58 0.14 to 2.65	0.57 0.24 to 1.33	0.52 0.13 to 2.16	0.51 0.24 to 1.07	0.45 0.18 to 1.14	0.44 0.17 to 1.21	0.43 0.17 to 1.00	0.41 0.03 to 3.31	0.39 0.10 to 1.37	0.30 0.09 to 1.00	0.28 0.01 to 7.99	0.28 0.10 to 0.78	0.20 0.03 to 1.09	0.17 0.05 to 0.54	0.17 0.03 to 0.87	0.17 0.01 to 2.19	0.14 0.04 to 0.44	0.10 0.00 to 1.92
METFORMIN	1.29 0.42 to 3.89	7.60 0.28 to 429	7.26 0.92 to 92.75	4.32 0.93 to 18.64	3.05 0.65 to 14.74	2.86 0.06 to 247	2.63 0.84 to 8.42	2.41 0.48 to 12.45	2.23 0.40 to 14.42	2.09 0.31 to 13.31	2.05 0.02 to 279	1.99 0.02 to 210	1.99 0.02 to 229	1.94 0.02 to 249	1.88 0.60 to 5.78	1.57 0.31 to 8.51	1.54 0.43 to 5.57	1.48 0.41 to 5.23	1.40 0.36 to 5.12	1.35 0.14 to 13.35	1.29 0.33 to 4.97	METFORMIN	0.97 0.32 to 2.91	0.94 0.12 to 6.62	0.88 0.28 to 2.87	0.83 0.07 to 16.03	0.80 0.02 to 22.54	0.80 0.23 to 2.52	0.78 0.24 to 2.48	0.76 0.20 to 2.97	0.72 0.22 to 2.32	0.67 0.14 to 3.24	0.66 0.21 to 2.06	0.57 0.18 to 1.92	0.57 0.17 to 1.97	0.55 0.17 to 1.68	0.51 0.04 to 4.95	0.48 0.10 to 2.11	0.38 0.09 to 1.58	0.37 0.01 to 11.05	0.35 0.10 to 1.30	0.26 0.04 to 1.50	0.22 0.05 to 0.88	0.21 0.03 to 1.39	0.21 0.01 to 3.03	0.18 0.04 to 0.71	0.13 0.00 to 2.63
EXENER_SC	1.33 0.83 to 2.08	7.97 0.33 to 417	7.44 1.33 to 81.12	4.45 1.44 to 13.44	3.13 1.01 to 10.89	2.97 0.07 to 231	2.71 1.62 to 4.86	2.51 0.82 to 8.54	2.27 0.58 to 11.12	2.17 0.42 to 9.63	2.15 0.02 to 250	2.13 0.03 to 194	2.07 0.03 to 214	1.98 0.02 to 244	1.95 1.15 to 3.32	1.64 0.48 to 6.33	1.60 0.78 to 3.43	1.54 0.68 to 3.29	1.45 0.32 to 6.08	1.39 0.18 to 11.16	1.33 0.55 to 3.26	1.03 0.34 to 3.15	EXENER_SC	0.98 0.15 to 5.83	0.92 0.51 to 1.63	0.86 0.08 to 13.54	0.84 0.02 to 20.99	0.83 0.41 to 1.52	0.81 0.43 to 1.45	0.78 0.23 to 2.84	0.75 0.43 to 1.30	0.70 0.21 to 2.34	0.68 0.40 to 1.12	0.60 0.34 to 1.06	0.59 0.33 to 1.09	0.57 0.34 to 0.92	0.53 0.05 to 3.81	0.51 0.16 to 1.42	0.40 0.14 to 1.06	0.38 0.01 to 10.25	0.37 0.16 to 0.82	0.27 0.05 to 1.20	0.23 0.09 to 0.59	0.22 0.04 to 1.10	0.22 0.01 to 2.47	0.19 0.07 to 0.48	0.14 0.01 to 2.26
DAPAGLIFLOZIN	1.36 0.24 to 8.37	8.61 0.23 to 568	7.94 0.67 to 142	4.61 0.60 to 37.15	3.31 0.44 to 29.55	3.11 0.05 to 341	2.77 0.46 to 18.88	2.60 0.31 to 23.89	2.40 0.26 to 25.54	2.28 0.22 to 23.61	2.18 0.02 to 381	2.17 0.02 to 308	2.24 0.02 to 272	2.11 0.02 to 324	2.00 0.34 to 12.93	1.66 0.21 to 16.23	1.64 0.25 to 12.01	1.55 0.23 to 11.29	1.46 0.20 to 11.75	1.44 0.10 to 24.38	1.36 0.20 to 9.89	1.07 0.15 to 8.28	1.02 0.17 to 6.74	DAPAGLIFLOZIN	0.94 0.15 to 6.32	0.90 0.05 to 23.61	0.84 0.02 to 34.39	0.84 0.13 to 5.63	0.83 0.13 to 5.36	0.80 0.10 to 7.70	0.76 0.13 to 4.91	0.71 0.08 to 6.21	0.70 0.11 to 4.57	0.60 0.10 to 4.22	0.60 0.09 to 4.14	0.58 0.09 to 3.75	0.52 0.03 to 8.17	0.52 0.07 to 4.20	0.41 0.06 to 3.20	0.40 0.01 to 15.48	0.37 0.06 to 2.76	0.28 0.06 to 0.92	0.23 0.03 to 1.74	0.23 0.02 to 2.43	0.22 0.01 to 5.17	0.19 0.03 to 1.49	0.14 0.00 to 4.13
DULA_SC	1.45 0.95 to 2.19	8.56 0.36 to 444	8.00 1.44 to 86.57	4.80 1.64 to 14.15	3.43 1.13 to 11.41	3.23 0.08 to 246	2.95 1.88 to 5.04	2.74 0.78 to 10.64	2.47 0.70 to 11.44	2.37 0.46 to 10.56	2.38 0.02 to 261	2.28 0.03 to 207	2.25 0.03 to 234	2.16 0.03 to 274	2.12 1.23 to 3.74	1.79 0.52 to 6.98	1.74 0.85 to 3.66	1.69 0.78 to 3.46	1.58 0.35 to 6.87	1.53 0.20 to 12.56	1.44 0.60 to 3.63	1.13 0.35 to 3.60	1.09 0.61 to 1.98	1.07 0.16 to 6.47	DULA_SC	0.92 0.09 to 15.43	0.91 0.02 to 23.10	0.90 0.46 to 1.59	0.89 0.51 to 1.47	0.84 0.24 to 3.34	0.82 0.47 to 1.38	0.75 0.23 to 2.55	0.74 0.43 to 1.28	0.65 0.37 to 1.16	0.64 0.34 to 1.29	0.62 0.36 to 1.04	0.59 0.06 to 4.29	0.55 0.17 to 1.59	0.43 0.15 to 1.13	0.42 0.01 to 11.02	0.40 0.18 to 0.90	0.30 0.05 to 1.29	0.25 0.10 to 0.63	0.24 0.04 to 1.19	0.25 0.01 to 2.70	0.20 0.07 to 0.54	0.15 0.01 to 2.43
OTHER_ACTIVE_basal_bolus_insulin	1.55 0.10 to 14.96	9.37 0.14 to 816	9.19 0.33 to 226	5.23 0.26 to 63.77	3.74 0.20 to 44.55	3.52 0.03 to 445	3.19 0.20 to 32.20	3.00 0.15 to 40.15	2.69 0.13 to 40.26	2.53 0.11 to 38.54	2.35 0.01 to 425	2.41 0.01 to 365	2.34 0.01 to 439	2.28 0.01 to 440	2.28 0.15 to 22.14	1.96 0.10 to 24.02	1.88 0.11 to 19.38	1.80 0.11 to 19.69	1.68 0.07 to 23.05	1.58 0.05 to 35.33	1.56 0.09 to 17.01	1.21 0.06 to 14.52	1.17 0.07 to 11.92	1.12 0.04 to 19.98	1.09 0.06 to 10.87	OTHER_ACTIVE_basal_bolus_insulin	0.95 0.01 to 50.74	0.97 0.06 to 9.72	0.95 0.06 to 9.64	0.90 0.04 to 12.85	0.88 0.06 to 8.82	0.80 0.04 to 10.03	0.80 0.05 to 8.05	0.69 0.04 to 7.15	0.69 0.04 to 7.13	0.67 0.04 to 6.22	0.60 0.02 to 12.32	0.58 0.03 to 6.73	0.46 0.03 to 5.21	0.44 0.01 to 24.91	0.42 0.02 to 4.53	0.31 0.01 to 4.97	0.26 0.02 to 3.19	0.25 0.01 to 4.00	0.24 0.00 to 7.51	0.22 0.01 to 2.41	0.15 0.00 to 5.71
ECNO_SC	1.56 0.07 to 62.14	10.36 0.11 to 1871	9.48 0.23 to 654	5.28 0.18 to 241	3.88 0.13 to 164	3.67 0.03 to 945	3.25 0.13 to 131	3.06 0.10 to 142	2.88 0.08 to 146	2.58 0.07 to 131	2.55 0.01 to 927	2.59 0.01 to 766	2.60 0.01 to 761	2.62 0.01 to 856	2.30 0.09 to 94.83	1.99 0.07 to 92.44	1.90 0.07 to 77.72	1.82 0.07 to 72.66	1.72 0.05 to 88.78	1.68 0.04 to 108	1.58 0.06 to 66.68	1.25 0.04 to 54.64	1.19 0.05 to 47.01	1.20 0.03 to 63.55	1.10 0.04 to 43.83	1.05 0.02 to 92.94	ECNO_SC	0.97 0.04 to 38.54	0.95 0.04 to 40.14	0.94 0.03 to 41.98	0.88 0.04 to 34.27	0.84 0.03 to 38.07	0.80 0.03 to 31.33	0.71 0.03 to 28.49	0.69 0.03 to 29.69	0.68 0.03 to 26.28	0.63 0.01 to 38.12	0.59 0.02 to 26.46	0.47 0.02 to 19.49	0.47 0.00 to 52.42	0.44 0.02 to 18.62	0.32 0.01 to 16.45	0.27 0.01 to 11.63	0.26 0.01 to 14.05	0.27 0.00 to 21.11	0.22 0.01 to 9.62	0.16 0.00 to 17.43
ALBI_SC	1.60 1.04 to 2.80	9.67 0.37 to 520	9.02 1.60 to 96.52	5.39 1.82 to 16.66	3.83 1.26 to 13.88	3.68 0.09 to 294	3.28 1.90 to 6.68	3.10 0.86 to 12.15	2.80 0.70 to 13.98	2.66 0.51 to 12.49	2.65 0.03 to 304	2.56 0.03 to 238	2.53 0.03 to 271	2.42 0.03 to 292	2.34 1.36 to 4.75	2.01 0.59 to 7.95	1.95 0.93 to 4.44	1.87 0.91 to 3.83	1.74 0.38 to 7.99	1.71 0.22 to 14.33	1.59 0.68 to 4.35	1.25 0.40 to 4.41	1.21 0.66 to 2.46	1.19 0.18 to 7.56	1.11 0.63 to 2.19	1.04 0.10 to 17.65	1.03 0.03 to 25.50	ALBI_SC	0.98 0.55 to 1.85	0.94 0.27 to 3.91	0.90 0.51 to 1.79	0.84 0.24 to 3.17	0.82 0.48 to 1.58	0.72 0.40 to 1.45	0.70 0.37 to 1.58	0.69 0.40 to 1.31	0.67 0.06 to 5.01	0.62 0.18 to 1.88	0.48 0.17 to 1.35	0.46 0.01 to 12.15	0.44 0.20 to 1.09	0.34 0.05 to 1.50	0.28 0.11 to 0.78	0.27 0.04 to 1.35	0.27 0.01 to 3.11	0.23 0.08 to 0.65	0.17 0.01 to 2.86
TIRZ_SC	1.63 1.05 to 2.64	9.75 0.40 to 515	9.10 1.61 to 102	5.42 2.12 to 14.86	3.87 1.26 to 13.34	3.73 0.09 to 283	3.33 2.12 to 5.82	3.11 0.89 to 12.01	2.84 0.72 to 13.83	2.68 0.54 to 12.00	2.62 0.03 to 297	2.59 0.03 to 241	2.55 0.03 to 258	2.49 0.03 to 296	2.39 1.37 to 4.51	2.00 0.60 to 7.87	1.97 0.97 to 4.28	1.90 0.99 to 3.63	1.78 0.39 to 7.93	1.72 0.22 to 13.93	1.62 0.67 to 4.30	1.28 0.40 to 4.14	1.23 0.69 to 2.33	1.21 0.19 to 7.62	1.13 0.68 to 1.96	1.06 0.10 to 16.76	1.06 0.02 to 26.98	1.02 0.54 to 1.83	TIRZ_SC	0.95 0.27 to 3.84	0.92 0.52 to 1.67	0.85 0.25 to 3.07	0.84 0.48 to 1.53	0.74 0.41 to 1.37	0.72 0.38 to 1.50	0.71 0.40 to 1.21	0.67 0.07 to 5.05	0.63 0.20 to 1.82	0.49 0.17 to 1.34	0.48 0.01 to 12.50	0.45 0.20 to 1.09	0.34 0.06 to 1.50	0.29 0.11 to 0.76	0.27 0.05 to 1.40	0.27 0.01 to 3.12	0.23 0.08 to 0.64	0.17 0.01 to 2.74
PIOGLITAZONE	1.72 0.47 to 5.73	10.12 0.32 to 626	9.68 1.08 to 134	5.70 1.10 to 27.31	4.06 0.74 to 20.45	3.82 0.08 to 326	3.49 0.92 to 12.48	3.25 0.56 to 17.56	2.98 0.45 to 20.22	2.77 0.36 to 18.64	2.71 0.02 to 384	2.67 0.03 to 302	2.65 0.03 to 309	2.58 0.03 to 352	2.53 0.67 to 8.58	2.10 0.38 to 11.97	2.05 0.48 to 8.10	1.98 0.45 to 7.67	1.85 0.29 to 9.84	1.80 0.16 to 19.36	1.71 0.38 to 7.36	1.32 0.34 to 4.89	1.29 0.35 to 4.28	1.25 0.13 to 10.37	1.20 0.30 to 4.12	1.11 0.08 to 22.87	1.07 0.02 to 33.02	1.06 0.26 to 3.75	1.05 0.26 to 3.65	PIOGLITAZONE	0.97 0.25 to 3.34	0.89 0.16 to 4.92	0.88 0.23 to 3.02	0.77 0.20 to 2.72	0.76 0.19 to 2.80	0.74 0.19 to 2.45	0.67 0.05 to 6.89	0.65 0.11 to 3.08	0.51 0.10 to 2.30	0.49 0.01 to 14.93	0.47 0.11 to 1.84	0.34 0.04 to 2.18	0.30 0.06 to 1.27	0.28 0.03 to 2.07	0.28 0.01 to 4.39	0.24 0.05 to 1.04	0.18 0.01 to 3.69
SEMA_PO	1.78 1.20 to 2.60	10.75 0.41 to 560	9.73 1.78 to 105	5.94 1.92 to 17.85	4.20 1.37 to 13.55	3.99 0.10 to 298	3.63 2.15 to 6.54	3.35 0.98 to 12.85	3.05 0.77 to 14.95	2.91 0.56 to 12.91	2.91 0.03 to 329	2.85 0.04 to 269	2.77 0.04 to 296	2.64 0.03 to 314	2.59 1.72 to 4.07	2.18 0.65 to 8.21	2.15 1.04 to 4.52	2.07 0.93 to 4.37	1.95 0.43 to 8.27	1.85 0.24 to 14.62	1.76 0.75 to 4.25	1.38 0.43 to 4.54	1.33 0.77 to 2.33	1.32 0.20 to 7.82	1.22 0.72 to 2.11	1.14 0.11 to 18.10	1.13 0.03 to 27.65	1.11 0.56 to 1.95	1.09 0.60 to 1.91	1.03 0.30 to 4.04	SEMA_PO	0.93 0.27 to 3.15	0.91 0.58 to 1.43	0.79 0.46 to 1.40	0.79 0.41 to 1.60	0.77 0.46 to 1.21	0.71 0.07 to 5.20	0.68 0.22 to 1.90	0.53 0.19 to 1.38	0.51 0.01 to 13.54	0.49 0.23 to 1.04	0.37 0.06 to 1.60	0.31 0.13 to 0.72	0.30 0.05 to 1.43	0.30 0.01 to 3.34	0.25 0.09 to 0.64	0.19 0.01 to 3.08
ICOSEMA_SC	1.93 0.59 to 6.26	11.58 0.37 to 657	10.73 1.37 to 139	6.38 1.30 to 31.56	4.60 1.00 to 21.21	4.26 0.09 to 434	3.96 1.17 to 13.78	3.65 0.69 to 21.07	3.34 0.56 to 22.02	3.11 0.44 to 21.24	3.12 0.03 to 405	3.07 0.04 to 329	3.00 0.03 to 354	2.83 0.03 to 386	2.81 0.85 to 9.34	2.39 0.46 to 12.27	2.31 0.63 to 8.79	2.23 0.55 to 8.58	2.06 0.34 to 12.71	2.03 0.19 to 21.38	1.93 0.46 to 7.68	1.49 0.31 to 7.32	1.44 0.43 to 4.79	1.40 0.16 to 11.93	1.33 0.39 to 4.44	1.25 0.10 to 22.36	1.19 0.03 to 35.02	1.19 0.32 to 4.10	1.17 0.33 to 4.00	1.13 0.20 to 6.36	1.08 0.32 to 3.65	ICOSEMA_SC	0.98 0.29 to 3.33	0.86 0.25 to 3.03	0.86 0.23 to 3.08	0.82 0.26 to 2.46	0.77 0.06 to 7.43	0.74 0.15 to 3.42	0.57 0.13 to 2.52	0.55 0.01 to 17.72	0.53 0.14 to 2.05	0.39 0.05 to 2.50	0.33 0.07 to 1.39	0.32 0.04 to 2.10	0.32 0.01 to 4.61	0.27 0.06 to 1.19	0.20 0.01 to 4.25
LIRA_SC	1.96 1.33 to 2.79	11.78 0.47 to 609	10.94 1.93 to 111	6.53 2.13 to 19.68	4.63 1.54 to 15.29	4.40 0.11 to 331	3.99 2.38 to 7.17	3.72 1.09 to 13.81	3.35 0.86 to 16.21	3.21 0.62 to 14.36	3.16 0.03 to 364	3.12 0.04 to 286	3.04 0.04 to 312	2.93 0.04 to 346	2.86 1.89 to 4.45	2.42 0.72 to 9.16	2.36 1.15 to 4.95	2.27 1.03 to 4.70	2.12 0.48 to 9.01	2.05 0.27 to 16.31	1.96 0.93 to 4.19	1.52 0.48 to 4.84	1.47 0.89 to 2.48	1.43 0.22 to 8.74	1.35 0.78 to 2.32	1.25 0.12 to 19.68	1.25 0.03 to 30.67	1.22 0.63 to 2.10	1.19 0.65 to 2.07	1.14 0.33 to 4.37	1.10 0.70 to 1.74	1.02 0.30 to 3.43	LIRA_SC	0.88 0.51 to 1.52	0.86 0.46 to 1.70	0.85 0.51 to 1.33	0.80 0.08 to 5.56	0.76 0.23 to 2.09	0.59 0.20 to 1.49	0.56 0.02 to 14.56	0.54 0.25 to 1.14	0.40 0.07 to 1.81	0.34 0.13 to 0.82	0.33 0.06 to 1.43	0.33 0.01 to 3.66	0.28 0.11 to 0.64	0.21 0.01 to 3.39
LIXI_SC	2.23 1.41 to 3.41	13.49 0.53 to 706	12.21 2.26 to 128	7.45 2.43 to 22.31	5.30 1.69 to 17.97	4.99 0.13 to 380	4.56 2.76 to 8.05	4.22 1.21 to 16.39	3.87 0.96 to 19.62	3.67 0.70 to 16.22	3.60 0.04 to 390	3.57 0.04 to 332	3.53 0.05 to 357	3.24 0.04 to 400	3.26 1.90 to 5.71	2.75 0.77 to 10.54	2.68 1.50 to 5.06	2.58 1.12 to 5.44	2.43 0.50 to 10.69	2.34 0.30 to 18.76	2.24 0.88 to 5.59	1.76 0.52 to 5.68	1.68 0.94 to 2.94	1.65 0.24 to 9.82	1.54 0.86 to 2.67	1.44 0.14 to 22.58	1.41 0.04 to 34.22	1.39 0.69 to 2.49	1.36 0.73 to 2.42	1.30 0.37 to 5.04	1.26 0.71 to 2.16	1.16 0.33 to 4.00	1.14 0.66 to 1.95	LIXI_SC	0.98 0.56 to 1.80	0.96 0.54 to 1.64	0.89 0.09 to 6.68	0.85 0.26 to 2.46	0.67 0.23 to 1.77	0.64 0.02 to 16.88	0.62 0.27 to 1.41	0.46 0.07 to 2.05	0.39 0.14 to 0.99	0.37 0.06 to 1.82	0.37 0.01 to 4.21	0.31 0.11 to 0.82	0.24 0.01 to 3.82
EXEN_SC	2.26 1.22 to 3.93	13.23 0.53 to 702	12.32 2.43 to 127	7.55 2.25 to 23.62	5.39 1.58 to 18.37	5.07 0.12 to 404	4.62 2.55 to 8.65	4.28 1.22 to 16.25	3.91 0.93 to 19.38	3.71 0.68 to 17.24	3.57 0.04 to 425	3.62 0.04 to 335	3.48 0.05 to 381	3.38 0.04 to 429	3.32 1.69 to 6.33	2.82 0.73 to 10.97	2.74 1.26 to 5.78	2.62 1.12 to 5.70	2.44 0.51 to 11.08	2.38 0.29 to 19.58	2.27 0.83 to 5.84	1.76 0.51 to 5.86	1.70 0.92 to 3.02	1.66 0.24 to 10.53	1.56 0.77 to 2.95	1.45 0.14 to 23.46	1.45 0.03 to 36.01	1.42 0.63 to 2.74	1.38 0.66 to 2.63	1.32 0.36 to 5.32	1.27 0.63 to 2.41	1.17 0.32 to 4.26	1.16 0.59 to 2.16	1.02 0.56 to 1.77	EXEN_SC	0.97 0.49 to 1.82	0.91 0.09 to 6.86	0.87 0.24 to 2.65	0.68 0.21 to 1.89	0.65 0.02 to 16.51	0.63 0.24 to 1.49	0.46 0.07 to 2.15	0.39 0.14 to 1.03	0.37 0.06 to 1.90	0.38 0.01 to 4.30	0.32 0.11 to 0.86	0.24 0.01 to 3.83
SEMA_SC	2.31 1.64 to 3.42	13.94 0.56 to 738	12.99 2.33 to 141	7.78 2.55 to 23.31	5.48 2.09 to 17.05	5.22 0.13 to 414	4.74 2.91 to 8.70	4.44 1.30 to 16.25	4.03 1.04 to 19.65	3.83 0.75 to 16.91	3.79 0.04 to 425	3.75 0.05 to 337	3.67 0.05 to 377	3.45 0.04 to 424	3.40 2.28 to 5.46	2.86 0.97 to 10.15	2.82 1.40 to 5.99	2.70 1.26 to 5.64	2.54 0.56 to 10.90	2.45 0.33 to 20.24	2.30 1.00 to 5.89	1.82 0.59 to 5.78	1.75 1.09 to 2.96	1.72 0.27 to 10.53	1.61 0.96 to 2.78	1.50 0.16 to 22.34	1.47 0.04 to 36.48	1.46 0.77 to 2.51	1.42 0.83 to 2.49	1.35 0.41 to 5.28	1.31 0.82 to 2.19	1.22 0.41 to 3.86	1.18 0.75 to 1.95	1.04 0.61 to 1.85	1.03 0.55 to 2.06	SEMA_SC	0.95 0.10 to 6.92	0.89 0.28 to 2.51	0.70 0.25 to 1.82	0.68 0.02 to 17.25	0.64 0.30 to 1.38	0.48 0.08 to 2.12	0.41 0.16 to 1.00	0.39 0.06 to 1.87	0.39 0.02 to 4.28	0.33 0.12 to 0.85	0.25 0.01 to 4.00
VISEPE_SC	2.47 0.36 to 23.92	15.75 0.35 to 1262	14.77 1.08 to 345	8.46 0.90 to 94.14	6.01 0.62 to 72.71	5.74 0.09 to 715	5.07 0.69 to 49.81	4.79 0.50 to 61.33	4.42 0.39 to 71.06	4.13 0.35 to 57.06	4.25 0.03 to 707	4.04 0.03 to 612	4.05 0.03 to 625	3.74 0.03 to 831	3.66 0.50 to 36.79	3.12 0.31 to 41.44	3.02 0.39 to 31.74	2.85 0.37 to 29.35	2.76 0.22 to 39.51	2.64 0.17 to 54.66	2.46 0.30 to 28.73	1.97 0.20 to 24.28	1.88 0.26 to 19.10	1.91 0.12 to 30.12	1.69 0.23 to 17.53	1.66 0.08 to 59.86	1.60 0.03 to 75.22	1.50 0.20 to 15.47	1.50 0.20 to 15.37	1.49 0.15 to 19.91	1.40 0.19 to 13.33	1.29 0.13 to 17.25	1.25 0.18 to 12.68	1.12 0.15 to 11.27	1.09 0.15 to 11.52	1.06 0.14 to 10.34	VISEPE_SC	0.95 0.10 to 10.43	0.75 0.08 to 8.30	0.73 0.01 to 35.75	0.69 0.09 to 7.21	0.51 0.04 to 7.37	0.43 0.05 to 4.87	0.41 0.03 to 6.53	0.41 0.01 to 11.82	0.35 0.04 to 4.01	0.26 0.01 to 9.40
DANU_PO	2.60 0.99 to 7.70	15.89 0.56 to 954	14.97 2.00 to 185	8.74 2.06 to 38.65	6.23 1.51 to 30.27	5.94 0.12 to 536	5.36 1.90 to 17.59	4.98 1.02 to 27.27	4.56 0.88 to 30.03	4.33 0.63 to 26.51	4.33 0.04 to 505	4.11 0.04 to 459	4.14 0.05 to 474	4.03 0.04 to 512	3.81 1.36 to 12.53	3.26 0.70 to 17.03	3.18 1.00 to 11.34	3.06 0.88 to 10.67	2.87 0.49 to 17.10	2.77 0.29 to 28.08	2.60 0.73 to 10.49	2.06 0.47 to 9.80	1.97 0.70 to 6.40	1.94 0.24 to 14.99	1.81 0.63 to 5.76	1.71 0.15 to 33.12	1.68 0.04 to 51.50	1.61 0.53 to 5.43	1.59 0.55 to 5.02	1.54 0.32 to 8.87	1.47 0.53 to 4.61	1.36 0.29 to 6.52	1.32 0.48 to 4.39	1.17 0.41 to 3.82	1.15 0.38 to 4.13	1.12 0.40 to 3.54	1.06 0.10 to 9.68	DANU_PO	0.79 0.20 to 3.13	0.75 0.02 to 23.28	0.72 0.22 to 2.72	0.53 0.07 to 3.23	0.45 0.12 to 1.77	0.44 0.06 to 2.82	0.44 0.01 to 6.18	0.36 0.10 to 1.50	0.28 0.01 to 5.41
EFPE_SC	3.34 1.39 to 8.80	20.43 0.76 to 1129	18.95 2.68 to 228	11.32 2.82 to 45.62	8.04 2.03 to 35.58	7.63 0.17 to 616	6.86 2.62 to 20.52	6.41 1.40 to 32.97	5.87 1.17 to 36.82	5.58 0.83 to 32.54	5.39 0.05 to 687	5.27 0.06 to 561	5.38 0.06 to 593	5.07 0.06 to 608	4.91 1.86 to 14.14	4.17 0.93 to 20.92	4.09 1.36 to 13.14	3.89 1.26 to 12.70	3.69 0.64 to 20.50	3.49 0.39 to 32.91	3.33 1.00 to 11.76	2.64 0.63 to 11.08	2.52 0.94 to 7.32	2.47 0.31 to 18.17	2.30 0.88 to 6.66	2.18 0.19 to 38.56	2.14 0.05 to 57.94	2.08 0.74 to 5.73	2.04 0.75 to 5.98	1.97 0.43 to 9.71	1.89 0.72 to 5.33	1.75 0.40 to 7.95	1.70 0.67 to 4.93	1.50 0.57 to 4.35	1.48 0.53 to 4.68	1.44 0.55 to 3.99	1.33 0.12 to 12.89	1.27 0.32 to 4.97	EFPE_SC	0.97 0.02 to 27.22	0.92 0.30 to 3.14	0.70 0.10 to 3.80	0.58 0.16 to 2.15	0.56 0.08 to 3.32	0.57 0.02 to 7.48	0.47 0.13 to 1.76	0.35 0.01 to 6.87
BGM050_SC	3.42 0.14 to 119	22.30 0.22 to 3985	20.71 0.53 to 1360	11.75 0.40 to 436	8.53 0.29 to 331	8.46 0.06 to 1888	7.10 0.27 to 251	6.67 0.21 to 285	6.10 0.19 to 276	5.70 0.16 to 253	5.75 0.02 to 1937	5.51 0.03 to 1491	5.82 0.03 to 1673	5.34 0.02 to 1767	5.16 0.20 to 180	4.34 0.13 to 172	4.20 0.15 to 150	3.99 0.14 to 133	3.78 0.11 to 164	3.75 0.08 to 210	3.61 0.13 to 130	2.68 0.09 to 103	2.64 0.10 to 91.56	2.53 0.06 to 132	2.39 0.09 to 81.82	2.29 0.04 to 185	2.13 0.02 to 259	2.17 0.08 to 75.04	2.08 0.08 to 74.33	2.06 0.07 to 78.24	1.96 0.07 to 69.68	1.81 0.06 to 74.07	1.78 0.07 to 64.34	1.55 0.06 to 54.16	1.54 0.06 to 54.40	1.48 0.06 to 51.27	1.37 0.03 to 74.20	1.34 0.04 to 49.03	1.03 0.04 to 40.03	BGM050_SC	0.95 0.03 to 35.34	0.69 0.02 to 30.95	0.61 0.02 to 21.52	0.57 0.02 to 25.65	0.55 0.01 to 41.61	0.48 0.02 to 18.61	0.36 0.00 to 31.72
TASP_SC	3.62 1.76 to 7.47	21.90 0.81 to 1196	20.28 3.29 to 230	12.24 3.26 to 42.18	8.64 2.45 to 32.28	8.20 0.19 to 630	7.40 3.43 to 17.54	6.90 1.66 to 29.97	6.26 1.42 to 34.15	5.97 1.02 to 30.02	5.96 0.06 to 723	5.67 0.07 to 555	5.74 0.07 to 597	5.50 0.06 to 681	5.29 2.73 to 10.73	4.45 1.14 to 19.34	4.40 1.67 to 11.46	4.23 1.53 to 11.05	3.90 0.79 to 19.38	3.81 0.45 to 33.04	3.60 1.28 to 10.50	2.82 0.77 to 10.19	2.73 1.22 to 6.20	2.67 0.36 to 17.06	2.49 1.11 to 5.69	2.36 0.22 to 40.42	2.28 0.05 to 58.61	2.25 0.92 to 5.06	2.21 0.92 to 4.97	2.11 0.54 to 9.37	2.04 0.96 to 4.31	1.90 0.49 to 7.24	1.84 0.88 to 3.98	1.62 0.71 to 3.76	1.59 0.67 to 4.09	1.56 0.72 to 3.35	1.44 0.14 to 11.74	1.39 0.37 to 4.60	1.09 0.32 to 3.37	1.05 0.03 to 28.96	TASP_SC	0.75 0.11 to 3.70	0.63 0.21 to 1.86	0.61 0.09 to 3.14	0.61 0.02 to 7.19	0.51 0.16 to 1.57	0.38 0.02 to 6.83
SAFIGL_PO	4.78 1.17 to 28.92	31.27 0.88 to 1996	28.21 2.95 to 470	16.37 2.78 to 122	11.79 1.94 to 91.77	11.27 0.21 to 1200	9.90 2.30 to 60.82	9.36 1.42 to 79.44	8.61 1.16 to 83.56	8.20 0.93 to 79.11	8.17 0.06 to 1218	8.24 0.08 to 1079	8.12 0.08 to 975	7.43 0.07 to 1081	7.09 1.59 to 42.73	6.06 0.93 to 51.89	5.91 1.24 to 38.18	5.58 1.13 to 36.39	5.25 0.83 to 42.61	5.25 0.43 to 78.63	4.89 0.92 to 32.97	3.83 0.67 to 28.29	3.64 0.83 to 21.96	3.51 1.09 to 15.56	3.33 0.77 to 20.48	3.19 0.20 to 81.95	3.13 0.06 to 133	2.94 0.67 to 18.25	2.92 0.67 to 17.99	2.91 0.46 to 25.47	2.69 0.62 to 16.57	2.58 0.40 to 20.46	2.49 0.55 to 14.90	2.17 0.49 to 13.39	2.15 0.46 to 13.81	2.07 0.47 to 12.46	1.95 0.14 to 27.91	1.87 0.31 to 13.42	1.43 0.26 to 10.38	1.44 0.03 to 53.70	1.33 0.27 to 9.11	SAFIGL_PO	0.84 0.16 to 6.01	0.81 0.09 to 7.76	0.81 0.02 to 16.01	0.69 0.12 to 4.68	0.52 0.02 to 13.79
LOTI_PO	5.70 2.50 to 14.14	34.89 1.29 to 1861	32.63 4.88 to 372	19.25 4.90 to 72.93	13.82 3.53 to 59.88	12.84 0.29 to 1037	11.75 4.73 to 32.83	10.92 2.56 to 53.17	10.08 2.09 to 59.21	9.53 1.56 to 50.50	9.41 0.09 to 1135	9.06 0.11 to 901	9.06 0.11 to 1018	8.61 0.10 to 1118	8.40 3.53 to 22.30	7.06 1.67 to 34.41	6.96 2.48 to 20.80	6.66 2.21 to 19.92	6.24 1.15 to 35.40	6.06 0.68 to 57.40	5.76 1.84 to 19.26	4.47 1.13 to 19.16	4.27 1.70 to 11.69	4.27 0.58 to 29.58	3.98 1.59 to 10.35	3.77 0.31 to 66.53	3.67 0.09 to 95.92	3.58 1.28 to 9.43	3.51 1.32 to 9.48	3.36 0.79 to 17.39	3.21 1.40 to 7.89	3.01 0.72 to 13.53	2.92 1.22 to 7.72	2.57 1.01 to 6.99	2.54 0.97 to 7.32	2.46 1.00 to 6.37	2.31 0.21 to 20.11	2.21 0.57 to 8.11	1.73 0.47 to 6.07	1.63 0.05 to 47.24	1.59 0.54 to 4.76	1.19 0.17 to 6.36	LOTI_PO	0.97 0.14 to 5.59	0.97 0.03 to 12.15	0.80 0.24 to 2.81	0.61 0.02 to 10.98
LIRAGL_SC	5.91 1.30 to 34.63	38.48 1.03 to 2558	35.31 3.50 to 589	20.08 3.13 to 164	14.38 2.22 to 117	14.04 0.23 to 1475	12.15 2.56 to 75.97	11.53 1.67 to 98.70	10.51 1.31 to 109	10.05 1.07 to 95.53	9.89 0.08 to 1474	9.90 0.10 to 1209	10.00 0.09 to 1278	9.28 0.09 to 1436	8.76 1.90 to 54.12	7.46 1.09 to 65.63	7.25 1.39 to 47.09	6.91 1.28 to 44.01	6.55 0.79 to 63.85	6.35 0.50 to 92.82	5.96 1.15 to 38.83	4.74 0.72 to 37.02	4.49 0.91 to 28.52	4.44 0.41 to 53.28	4.12 0.84 to 24.79	3.93 0.25 to 102	3.87 0.07 to 146	3.69 0.74 to 22.66	3.65 0.72 to 21.97	3.56 0.48 to 32.23	3.35 0.70 to 20.13	3.17 0.48 to 25.74	3.04 0.70 to 17.82	2.68 0.55 to 16.71	2.69 0.53 to 17.57	2.54 0.53 to 15.50	2.42 0.15 to 32.78	2.27 0.35 to 16.78	1.78 0.30 to 13.21	1.75 0.04 to 62.55	1.65 0.32 to 11.11	1.23 0.13 to 11.53	1.03 0.18 to 7.20	LIRAGL_SC	1.03 0.03 to 19.12	0.84 0.15 to 5.85	0.65 0.02 to 18.03
HRS7535_PO	5.93 0.54 to 157	40.66 0.62 to 4937	35.39 1.72 to 1668	19.75 1.45 to 567	14.25 1.03 to 459	14.80 0.16 to 3100	12.21 1.08 to 333	11.69 0.80 to 359	10.53 0.63 to 385	9.83 0.58 to 345	9.93 0.06 to 3098	10.30 0.06 to 2716	10.15 0.06 to 2476	9.66 0.06 to 2585	8.71 0.81 to 237	7.38 0.52 to 229	7.16 0.60 to 200	6.79 0.58 to 192	6.62 0.38 to 236	6.56 0.26 to 286	5.92 0.46 to 175	4.66 0.33 to 144	4.45 0.41 to 121	4.52 0.19 to 169	4.08 0.37 to 113	4.21 0.13 to 255	3.75 0.05 to 347	3.64 0.32 to 104	3.65 0.32 to 97.53	3.54 0.23 to 115	3.36 0.30 to 92.50	3.16 0.22 to 95.87	3.02 0.27 to 81.97	2.68 0.24 to 72.70	2.62 0.23 to 71.81	2.56 0.23 to 66.41	2.45 0.08 to 97.89	2.26 0.16 to 70.24	1.75 0.13 to 52.44	1.81 0.02 to 158	1.63 0.14 to 47.12	1.23 0.06 to 43.11	1.03 0.08 to 29.04	0.97 0.05 to 36.55	HRS7535_PO	0.84 0.06 to 24.43	0.65 0.01 to 41.83
COTA_SC	7.10 2.94 to 17.63	43.41 1.57 to 2419	40.10 5.90 to 445	24.18 5.73 to 94.43	17.08 4.29 to 72.91	15.94 0.37 to 1297	14.55 5.70 to 40.72	13.63 3.04 to 64.70	12.41 2.48 to 72.17	11.81 1.90 to 65.17	11.38 0.11 to 1304	11.44 0.13 to 1120	11.17 0.15 to 1176	10.50 0.12 to 1400	10.39 4.21 to 28.09	8.86 2.02 to 42.08	8.61 2.93 to 26.35	8.31 2.62 to 25.00	7.87 1.42 to 40.96	7.52 0.83 to 70.46	7.10 2.25 to 22.87	5.56 1.40 to 23.57	5.37 2.08 to 14.72	5.28 0.67 to 37.67	4.93 1.85 to 13.71	4.62 0.41 to 86.83	4.54 0.10 to 132	4.40 1.53 to 12.14	4.39 1.57 to 12.17	4.18 0.96 to 20.81	4.00 1.56 to 10.65	3.76 0.84 to 15.82	3.63 1.56 to 9.15	3.20 1.22 to 8.75	3.17 1.16 to 9.23	3.07 1.18 to 8.12	2.90 0.25 to 25.29	2.74 0.67 to 10.47	2.14 0.57 to 7.72	2.07 0.05 to 54.47	1.97 0.64 to 6.09	1.45 0.21 to 8.26	1.24 0.36 to 4.19	1.19 0.17 to 6.58	1.19 0.04 to 17.27	COTA_SC	0.76 0.03 to 14.25
DULAMACU_SC	9.37 0.60 to 233	62.44 0.76 to 8192	55.69 2.05 to 2424	31.46 1.59 to 902	23.11 1.10 to 630	20.75 0.41 to 4449	19.66 1.18 to 483	18.40 0.84 to 525	16.39 0.78 to 554	15.41 0.66 to 508	15.74 0.07 to 4301	15.41 0.09 to 4285	15.77 0.09 to 3636	14.60 0.09 to 4077	13.82 0.83 to 347	11.97 0.57 to 351	11.51 0.69 to 288	10.97 0.63 to 291	10.31 0.47 to 319	10.17 0.31 to 437	9.59 0.52 to 249	7.57 0.38 to 202	7.09 0.44 to 173	6.98 0.24 to 247	6.50 0.41 to 162	6.46 0.18 to 389	6.10 0.06 to 532	5.75 0.35 to 146	5.72 0.37 to 139	5.63 0.27 to 164	5.24 0.32 to 131	5.01 0.24 to 144	4.84 0.30 to 122	4.19 0.26 to 102	4.19 0.26 to 106	4.03 0.25 to 98.69	3.78 0.11 to 177	3.60 0.18 to 99.48	2.83 0.15 to 76.97	2.76 0.03 to 243	2.62 0.15 to 66.40	1.91 0.07 to 62.19	1.64 0.09 to 40.66	1.54 0.06 to 51.30	1.54 0.02 to 82.61	1.32 0.07 to 34.13	DULAMACU_SC

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.289 (95% CrI 0.095 to 0.503), log scale
Residual deviance: 238.6 for 233 data points
DIC: 388.8 (pD 150.2)
Largest R-hat: 1.007
Smallest ESS: bulk 724, tail 1,451
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-3.23, 1.79^2) on tau^2 (Withdrawals/drop-outs, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 93 of 110	Sex (percent female) effect modifier, prognostic factor; 104 of 110
SUSTAIN™ 3 S000329	not reported	44.53
AWARD-10 S000305	not reported	49.99
NCT03131687 S000010	1.66	46.85
NCT00754988 S000027	8.82	44.91
NCT05407961 S000034	not reported	23.57 100 minus male share
NCT01296412 S000080	not reported	45 100 minus male share
NCT00838916 S000099	5.13 Asian subgroup rows	43.94
SURPASS-6 S000108	0.57	57.68
PIONEER 4 S000133	13.4	48
NCT04965506 S000140	100	40.79
REWIND S000147	4.38	46.35
COMBINE 2 S000155	27.65	41.87
SCALE™ Insulin S000159	2	52.27
STEP HFpEF DM S000161	12.31	44.33
Lixilan-O-AP S000170	100 region: all sites in Asia	47.4
NCT01476475 S000191	0.62	48.92
OUTSTAND-1 S000213	100	33.09
PB119 S000217	96.36 Asian subgroup rows	26.74
NCT01001104 S000232	100 region: all sites in Asia	26.19
PIONEER 10 S000234	100	25.74
AWARD-7 S000237	3.01	47.69
NCT01584232 S000246	100	28.51
NCT03235050 S000257	0.72	53.72
NCT04235959 S000277	100 region: all sites in Asia	45.83
NCT01029886 S000352	12	45.49
LIXILAN JP-L S000356	100 region: all sites in Asia	not reported
SUSTAIN 11 S000363	19.55	48.86
REMODEL S000395	14.15	23.56
SURPASS-1 S000407	35.15	48.31
NCT00976937 S000415	0.6	59.9 100 minus male share
NCT05579977 S000448	13.22	52.05
TRANSITION-T2D S000460	1.67	41.33
SUSTAIN 9 S000483	23.51	41.72
GETGOAL-L-ASIA S000488	100	52.09
LIRA-PRIME S000508	14.6	47.55
PIONEER 12 S000522	75.22	41.7
NCT00612794 S000536	100 region: all sites in Asia	40.37 100 minus male share
NCT06589765 S000558	100 region: all sites in Asia	35.68
NCT02008682 S000650	100 region: all sites in Asia	40.35
NCT03555994 S000670	not reported	33.33
NCT02229383 S000703	1.3	52.04 100 minus male share
NCT02081118 S000719	1.99	54.01
LIRAVIS S000773	not reported	71.4
NCT00434954 S000790	not reported	30.36
GetGoal-Duo1 S000792	19.5	50.22
NCT05759897 S000877	100 region: all sites in Asia	40.68
SUSTAIN™1 S000878	21.4	45.62
NCT02200991 S001003	100 region: all sites in Asia	37.5 100 minus male share
NCT00097500 S001020	not reported	34.78
NCT00894322 S001058	2.86	31.43
AWARD-CHN1 S001064	97.69	45.71
AWARD-8 S001068	1.7	55.86
NCT02465515 S001074	4.98 Asian subgroup rows	30.58
NCT01733758 S001075	not reported	not reported
LIRA-SWITCH™ S001119	not reported	40.5
DURATION-NEO-2 S001157	3.85	47.12
NCT05514535 S001161	9.61	44.19
NCT03985293 S001191	8.51	49.21
NCT06974825 S001200	100 region: all sites in Asia	48.15
DUALTM IX S001236	15.75	41.2 100 minus male share
SURPASS-4 S001287	3.5	37.51
SUSTAIN S001311	85.03	42.5
NCT00360334 S001323	not reported	31.49
NCT04552470 S001336	100	13.51
NCT01003184 S001355	4	32.88
SOLID-DKD S001370	100	26.07
PIONEER 6 S001381	19.79	31.64
AWARD-CHN2 S001404	81.52	44.77
NCT00917267 S001437	100 region: all sites in Asia	not reported
GETGOAL-X S001439	1.1	46.32
SUSTAIN™ S001498	100 region: all sites in Asia	28.47
NCT05486065 S001555	1.49	48.69
DUAL™ II China S001556	100	39.5
SURPASS-3 S001591	5.4	44.04
SURPASS-5 S001608	17.89	44.42
NCT00744926 S001638	not reported	not reported
NCT00641056 S001768	6	45.61
PIONEER 11 S001791	74.85	36.27
NCT01272232 S001792	2.25	49.76
SUSTAIN™ 5 S001872	16.67	43.83
SUSTAIN™ 2 S001876	25.1	not reported
NCT02229227 S001887	1.6 Asian subgroup rows	54.27
LIRAFLAME S001895	not reported	15.7
SURPASS-SWITCH S001940	1.42	48.18
NCT01632163 S001963	85.95	54.65 100 minus male share
NCT00676338 S001966	12.44 Asian subgroup rows	40.99
LIXILAN JP-O1 S002018	100 region: all sites in Asia	35.85
NCT03550378 S002039	0	48.8
AMPLITUDE-M S002081	not reported	46.06
SUSTAIN™ S002082	100 region: all sites in Asia	23.72
NCT02690883 S002088	100 region: all sites in Asia	30.45 100 minus male share
Lixilan-L-CN S002110	100 region: all sites in Asia	41.81 100 minus male share
NCT04998032 S002121	100 region: all sites in Asia	46.97
NCT03311724 S002256	3.6	40.54
PIONEER 3 S002267	13.14	47.16
GETGOAL-MONO S002333	23.43	47.28
S002858 S002858	5.35	35.35
S002904 S002904	100 region: all sites in Asia	36.67
S002947 S002947	100 region: all sites in Asia	35.85
S002951 S002951	100 region: all sites in Asia	36.57
S002969 S002969	not reported	77.78
S002984 S002984	100 region: all sites in Asia	50
S003009 S003009	100 region: all sites in Asia	48.75
S003041 S003041	100 region: all sites in Asia	28.57
S003047 S003047	not reported	21.73 100 minus male share
S003071 S003071	100 region: all sites in Asia	34.35
S003079 S003079	100 region: all sites in Asia	not reported
S003108 S003108	100 region: all sites in Asia	50 100 minus male share
S003426 S003426	100 region: all sites in Asia	62.05
S003442 S003442	not reported	100

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 23.6 (DULA_SC vs DULAMACU_SC vs OTHER_ACTIVE_macupatide) to 100.0 (DULA_SC vs LIRA_SC) percent female; threshold 15
FlagBaseline, Asian ancestry or region: design means range from 0.0 (COTA_SC vs PLACEBO) to 100.0 (BGM050_SC vs PLACEBO vs SEMA_SC) percent Asian; threshold 30
NoteOutcome assessment, time point: selected time points span 2 to 365.26 weeks
NoteOutcome assessment, analysis set: mixed: completers 1, full_analysis 4, modified_itt 8, other 3, randomized 17, safety 77
NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, ADA severe hypoglycemia 1, death from any cause 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, glucose below 3.0 mmol/L; no severe events in any arm 1, Hypoglycaemia reported as treatment emergent adverse event 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia glucose 3.9 mmol/L or lower; both events mild 1, hypoglycemia requiring medical assistance 1, hypoglycemia requiring third party assistance 1, investigator reported symptomatic hypoglycemia 1, level 2 hypoglycemia, glucose below 54 mg/dL 1, level 3 severe hypoglycemia 2, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, not stated 77, Patients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuation 1, serious AEs including 4 week follow up 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia 1, severe hypoglycemia by ADA classification 1, severe hypoglycemia needing third party assistance 1, severe hypoglycemia requiring assistance from another person 1, severe hypoglycemic events, adverse event of special interest 1, severe symptomatic hypoglycemia needing assistance 1, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery 1, severe, needing assistance of another person 1, severe, requiring assistance of another person 1, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1, symptomatic hypoglycemia confirmed below 3.3 mmol/L 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, TEAE leading to death 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1
NoteOutcome assessment, proportion method: mixed: not stated 104, observed 6
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 105, treatment_policy 2, while_on_treatment 3
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 1, not stated 106, treatment_policy 3
NoteRisk of bias, blinding: mixed: double_blind 61, not_reported 1, open_label 43, single_blind 5
NoteRisk of bias, funding: mixed: industry 100, mixed 3, non_industry 6, not_reported 1
NoteData handling, input conversions: arms_combined 44, count_from_percent 13, printed_denominator 18

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
SUSTAIN™ 3	56	safety	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2013	age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
AWARD-10	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin
NCT03131687	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT05407961	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out)
NCT01296412	26	safety	investigator reported symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
NCT00838916	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	52	safety	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
PIONEER 4	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
NCT04965506	24	safety	glucose below 3.0 mmol/L; no severe events in any arm	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
REWIND	365.26	randomized	not stated	not stated	not stated	not stated	treatment_policy	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
STEP HFpEF DM	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
Lixilan-O-AP	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT01476475	24	safety	Documented symptomatic, plasma glucose 3.9 mmol/L or lower	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB119	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	16	safety	serious AEs including 4 week follow up	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	52	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
AWARD-7	52	safety	Hypoglycaemia reported as treatment emergent adverse event	not stated	not stated	not stated	treatment_policy	treatment_policy	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	severe, needing assistance of another person	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT03235050	54	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin
NCT04235959	28	safety	hypoglycemia glucose 3.9 mmol/L or lower; both events mild	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more
NCT01029886	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
LIXILAN JP-L	26.43	randomized	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	open_label	industry	2016	Japanese adults; T2D over 1 year; HbA1c 7.5 to 9.5 on basal insulin plus 1 or 2 oral drugs
SUSTAIN 11	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
REMODEL	57	randomized	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	T2D with HbA1c 9.0 percent or less; eGFR 30 to 75; UACR 20 to under 5000 mg/g
SURPASS-1	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days
NCT00976937	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
NCT05579977	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
TRANSITION-T2D	26	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2021	age 18 to 75; HbA1c 7.5 or lower on basal bolus insulin up to 120 U per day
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
GETGOAL-L-ASIA	24	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
LIRA-PRIME	105	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; HbA1c 7.5 to 9.0 percent; stable metformin monotherapy
PIONEER 12	31	safety	ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent
NCT00612794	20	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	Japanese T2D age 20 to 75; weight 50 kg or more; HbA1c 6.5 to 10 percent; diet or oral drugs
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
NCT02008682	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	Chinese adults 18 to 80; HbA1c 7.0 to 10.0 on metformin; BMI 45 or lower
NCT03555994	9	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone
NCT02229383	38	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT02081118	22	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
LIRAVIS	2	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	not_reported	2016	adults with type 2 diabetes on one or two oral drugs; HbA1c 7 percent or more; eGFR 30 or more; incretin naive
NCT00434954	26	full_analysis	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2007	adults with T2D on metformin, HbA1c 6.5 to 10.0 percent
GetGoal-Duo1	24	safety	symptomatic hypoglycemia confirmed below 3.3 mmol/L	not stated	not stated	observed	not stated	not stated	double_blind	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™1	35	safety	severe hypoglycemia by ADA classification	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
NCT00097500	52	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2004	age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin
NCT00894322	12	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	industry	2009	adults with T2D on diet and exercise, metformin, TZD or both
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT02465515	140.89	safety	severe hypoglycemic events, adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	type 2 diabetes with established cardiovascular disease
NCT01733758	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout
LIRA-SWITCH™	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
DURATION-NEO-2	28	safety	minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
NCT03985293	20	safety	TEAE preferred term hypoglycemia, not necessarily protocol defined	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT06974825	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 19.5 to 35.0; no glucose lowering drug for 8 weeks
DUALTM IX	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; insulin naive type 2 diabetes on SGLT2 inhibitor with or without other oral drugs; HbA1c 7.0 to 11.0 percent; BMI 20 to 40
SURPASS-4	108	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents
SUSTAIN	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT00360334	26	full_analysis	severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
NCT04552470	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
NCT01003184	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
PIONEER 6	87	full_analysis	death from any cause	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	T2D; age 50 or more with CVD or CKD, or 60 or more with CV risk factors
AWARD-CHN2	52	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT00917267	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2009	Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs
GETGOAL-X	24	safety	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
SUSTAIN™	62	safety	severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
DUAL™ II China	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 24 or higher; HbA1c 7.5 or higher; basal insulin 20 to 50 U plus metformin
SURPASS-3	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	insulin naive; HbA1c 7.0 to 10.5 percent; BMI at least 25; metformin with or without SGLT2i; eGFR above 45
SURPASS-5	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin
NCT00744926	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
NCT00641056	84	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea
PIONEER 11	31	safety	ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
NCT01272232	68	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
SUSTAIN™ 2	56	safety	ADA severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	type 2 diabetes on metformin and or thiazolidinedione; HbA1c 7.0 to 10.5 percent
NCT02229227	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
LIRAFLAME	26	other	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2017	T2D; age above 50; HbA1c 48 mmol/mol or more; eGFR 30 or more
SURPASS-SWITCH	44	modified_itt	level 2 hypoglycemia, glucose below 54 mg/dL	not stated	not stated	observed	not stated	not stated	open_label	industry	2022	age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
NCT00676338	26	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive
LIXILAN JP-O1	52.43	safety	TEAE leading to death	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
NCT03550378	8.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT02690883	24	safety	Patients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuation	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	age 18 or older; eGFR 30 or more; UAER above 0.3 g/24 h
Lixilan-L-CN	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT04998032	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
NCT03311724	12	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
PIONEER 3	78	other	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2016	adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea
GETGOAL-MONO	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
S002858	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry		T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002904	24	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2014	age 20 or older; HbA1c 8.0 percent or more; diet or oral drugs; no insulin or GLP-1 RA
S002947	25	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S002951	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2022	age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
S002969	26	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 70; BMI 30 to 50; HbA1c 48 to below 97 mmol/mol; T2DM under 10 years; undergoing LAGB
S002984	24	randomized	severe hypoglycemia requiring assistance from another person	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2020	T2D age 45 or older; HbA1c 7.0 to 11.0 percent; metformin at least 3 months
S003009	24	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g
S003041	2	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 40 to 70; BMI below 30; HbA1c 6.0 to 8.5 percent
S003047	6	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003071	24	randomized	hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to under 80; HbA1c 6.9 to 9.4 percent NGSP; BMI 35 or less; on sulfonylurea
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months
S003108	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2012	T2D with coronary artery disease; no severe heart failure; creatinine up to 150 umol/L
S003426	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry		adults with type 2 diabetes; HbA1c 6.5 to 8.0 percent; BMI 30 to 35; stable metformin and empagliflozin
S003442	24	other	not stated	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2019	Women with T2D by ADA criteria; no weight loss drugs within 24 weeks

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	26	arm, events	2 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	26	arm, events	23 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	26	arm, events	6 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	122 / 388	arms_combined	R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	13 / 185		R0022521:Table 2
NCT05407961	A1	OTHER_ACTIVE_macupatide	12	arm, events	0 / 15		R0015193:Table 2
NCT05407961	A2	DULA_SC	12	arm, events	0 / 29		R0015193:Table 2
NCT05407961	A3	DULAMACU_SC	12	arm, events	2 / 28		R0015193:Table 2
NCT01296412	A1	SITAGLIPTIN	26	arm, events	8 / 326		R0026295:Table 3
NCT01296412	A2	LIRA_SC	26	arm, events	29 / 327		R0026295:Table 3
NCT00838916	A1	ALBI_SC	52	arm, events	35 / 516		R0025374:Table 2
NCT00838916	A2	INS_GLARGINE	52	arm, events	6 / 263		R0025374:Table 2
SURPASS-6	A1+A2+A3	TIRZ_SC	52	arm, events	43 / 717	arms_combined	R0009666:Table 3
SURPASS-6	A4	INS_LISPRO	52	arm, events	17 / 711		R0009666:Table 3
PIONEER 4	A1	SEMA_PO	52	arm, events	31 / 285		R0015836:Table 3
PIONEER 4	A2	LIRA_SC	52	arm, events	26 / 284		R0015836:Table 3
PIONEER 4	A3	PLACEBO	52	arm, events	5 / 142		R0015836:Table 3
NCT04965506	A1+A2+A3	MAZD_SC	24	arm, events	0 / 149	arms_combined	R0012443:Table 2
NCT04965506	A4	DULA_SC	24	arm, events	1 / 50		R0012443:Table 2
NCT04965506	A5	PLACEBO	24	arm, events	0 / 51		R0012443:Table 2
REWIND	A1	PLACEBO	365.26	arm, events	310 / 4,952		R0018537:Results
REWIND	A2	DULA_SC	365.26	arm, events	451 / 4,949		R0018537:Results
COMBINE 2	A1	ICOSEMA_SC	57	arm, events	8 / 342	count_from_percent	R0005851:Results
COMBINE 2	A2	SEMA_SC	57	arm, events	9 / 341	count_from_percent	R0005851:Results
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	15 / 198		R0024063:Table 3
SCALE™ Insulin	A2	PLACEBO	58	arm, events	6 / 198		R0024063:Table 3
STEP HFpEF DM	A1	SEMA_SC	52	arm, events	33 / 310		R0020223:Table 3
STEP HFpEF DM	A2	PLACEBO	52	arm, events	25 / 306		R0020223:Table 3
Lixilan-O-AP	A1	IGLARLIXI_SC	24	arm, events	13 / 351		R0013321:Table 3
Lixilan-O-AP	A2	INS_GLARGINE	24	arm, events	3 / 350		R0013321:Table 3
Lixilan-O-AP	A3	LIXI_SC	24	arm, events	18 / 177		R0013321:Table 3
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	6 / 161		R0021236:Table 2
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:Table 2
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, events	8 / 212	arms_combined	R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	0 / 72		R0011607:Table 3
PB119	A1	VISEPE_SC	24	arm, events	3 / 137		R0011471:Figure 1
PB119	A2	PLACEBO	24	arm, events	1 / 136		R0011471:Figure 1
NCT01001104	A1	PLACEBO	16	arm, events	0 / 37		R0015000:Table 3
NCT01001104	A2+A3+A4	DULA_SC	16	arm, events	4 / 108	arms_combined	R0015000:Table 3
PIONEER 10	A1+A2+A3	SEMA_PO	52	arm, events	20 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	52	arm, events	2 / 65		R0018421:Table 2
AWARD-7	A1	INS_GLARGINE	52	arm, events	12 / 194		R0017387:Table 2
AWARD-7	A2+A3	DULA_SC	52	arm, events	43 / 383	arms_combined	R0017387:Table 2
NCT01584232	A1	DULA_SC	26	arm, events	6 / 181		R0016159:Results
NCT01584232	A2	INS_GLARGINE	26	arm, events	2 / 180		R0016159:Results
NCT03235050	A1	PLACEBO	54	arm, events	5 / 112		R0016374:Figure 1
NCT03235050	A2	LIRA_SC	54	arm, events	2 / 110		R0016374:Figure 1
NCT03235050	A3+A4+A5	COTA_SC	54	arm, events	107 / 612	arms_combined	R0016374:Figure 1
NCT04235959	A1	PLACEBO	28	arm, events	1 / 4		R0019570:Table 2
NCT04235959	A3	TIRZ_SC	28	arm, events	0 / 10		R0019570:Table 2
AWARD-10	A1+A2	DULA_SC	24	arm, events	4 / 284	arms_combined	R0020348:p1
AWARD-10	A3	PLACEBO	24	arm, events	0 / 140		R0020348:p1
SUSTAIN™ 3	A1	SEMA_SC	56	arm, events	36 / 406	count_from_percent	R0013158:Supplement Table S4
SUSTAIN™ 3	A2	EXENER_SC	56	arm, events	29 / 407		R0020680:Supplement Figure S2
NCT01029886	A1	EXENER_SC	26	arm, events	12 / 461		R0011287:Table 3
NCT01029886	A2	LIRA_SC	26	arm, events	23 / 451		R0011287:Table 3
LIXILAN JP-L	A1	IGLARLIXI_SC	26.43	arm, events	5 / 255		R0008233:Supplement Table S1
LIXILAN JP-L	A2	INS_GLARGINE	26.43	arm, events	4 / 257		R0008233:Supplement Table S1
SUSTAIN 11	A1	SEMA_SC	52	arm, events	32 / 874		R0022346:Table 3
SUSTAIN 11	A2	INS_ASPART	52	arm, events	6 / 874		R0022346:Table 3
REMODEL	A1	SEMA_SC	57	arm, events	9 / 71		R0007381:Extended Data Table 5
REMODEL	A2	PLACEBO	57	arm, events	1 / 35		R0007381:Extended Data Table 5
SURPASS-1	A1+A2+A3	TIRZ_SC	44	arm, events	18 / 363	arms_combined	R0007531:Supplement Table S2
SURPASS-1	A4	PLACEBO	44	arm, events	3 / 115		R0007531:Supplement Table S2
NCT00976937	A1	LIXI_SC	24	arm, events	4 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	5 / 161		R0012687:Table 2
NCT05579977	A1+A8	PLACEBO	28	arm, events	5 / 139	arms_combined	R0004106:Supplement Table S3
NCT05579977	A10+A11+A12+A13+A2+A3+A4+A5+A6+A9	LOTI_PO	28	arm, events	138 / 690	arms_combined	R0004106:Supplement Table S3
NCT05579977	A7	SEMA_PO	28	arm, events	5 / 73		R0004106:Supplement Table S3
TRANSITION-T2D	A1	OTHER_ACTIVE_basal_bolus_insulin	26	arm, events	1 / 20		R0018231:Table 2
TRANSITION-T2D	A2	SEMA_SC	26	arm, events	2 / 40		R0018231:Table 2
SUSTAIN 9	A1	SEMA_SC	36	arm, events	13 / 151		R0021710:Table 2
SUSTAIN 9	A2	PLACEBO	36	arm, events	3 / 151		R0021710:Table 2
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	14 / 154		R0022626:Table 2
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	5 / 157		R0022626:Table 2
LIRA-PRIME	A1	LIRA_SC	105	arm, events	77 / 996		R0022482:Supplement Table S7
LIRA-PRIME	A2	OTHER_ACTIVE_investigator_choice_oral_drug	105	arm, events	41 / 995		R0022482:Supplement Table S7
PIONEER 12	A1+A2+A3	SEMA_PO	31	arm, events	68 / 1,082	arms_combined	R0019776:Table 3
PIONEER 12	A4	SITAGLIPTIN	31	arm, events	6 / 359		R0019776:Table 3
NCT00612794	A1	PLACEBO	20	arm, events	0 / 10	printed_denominator	R0027116:p5
NCT00612794	A2+A3	EXENER_SC	20	arm, events	0 / 19	printed_denominator;arms_combined	R0027116:p5
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	24 / 608	arms_combined	R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	3 / 202		R0029347:Table 3
NCT02008682	A1	LIRA_SC	26	arm, events	12 / 184		R0025836:Figure 1
NCT02008682	A2	SITAGLIPTIN	26	arm, events	3 / 184		R0025836:Figure 1
NCT03555994	A1	PLACEBO	9	arm, events	0 / 11		R0005744:Table 2
NCT03555994	A2	LIRA_SC	9	arm, events	0 / 10		R0005744:Table 2
NCT03555994	A3	COTA_SC	9	arm, events	0 / 9		R0005744:Table 2
NCT02229383	A1	EXENER_SC	38	arm, events	9 / 233		R0014763:Figure 1
NCT02229383	A2	PLACEBO	38	arm, events	4 / 231		R0014763:Figure 1
NCT02081118	A1	PLACEBO	22	arm, events	1 / 51		R0009733:Table 3
NCT02081118	A2+A3+A4	EFPE_SC	22	arm, events	21 / 157	printed_denominator;arms_combined	R0009733:Table 3
LIRAVIS	A1	LIRA_SC	2	arm, events	0 / 7		R0055449:Figure 1
LIRAVIS	A2	VILDAGLIPTIN	2	arm, events	0 / 7		R0055449:Figure 1
NCT00434954	A1	EXEN_SC	26	arm, events	13 / 248	count_from_percent	R0027127:Results
NCT00434954	A2	INS_PREMIX	26	arm, events	1 / 246	count_from_percent	R0027127:Results
GetGoal-Duo1	A1	PLACEBO	24	arm, events	9 / 223	count_from_percent	R0026107:Results
GetGoal-Duo1	A2	LIXI_SC	24	arm, events	19 / 223	count_from_percent	R0026107:Results
NCT05759897	A1	PLACEBO	16	arm, events	0 / 39	printed_denominator	R0002101:Table 3
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	7 / 155	printed_denominator;arms_combined	R0002101:Table 3
SUSTAIN™1	A1+A2	SEMA_SC	35	arm, events	15 / 259	arms_combined	R0021710:Table 2
SUSTAIN™1	A3	PLACEBO	35	arm, events	3 / 129		R0021710:Table 2
NCT02200991	A1	LIXI_SC	4.43	arm, events	2 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Table 3
NCT00097500	A1	EXEN_SC	52	arm, events	5 / 36		registry:flow
NCT00097500	A2	INS_GLARGINE	52	arm, events	0 / 33		registry:flow
NCT00894322	A1	EXENER_SC	12	arm, events	0 / 23		registry:outcomes
NCT00894322	A2	PLACEBO	12	arm, events	0 / 12		registry:outcomes
AWARD-CHN1	A1+A2	DULA_SC	26	arm, events	14 / 492	arms_combined	R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	3 / 245		R0014229:Table 2
AWARD-8	A1	DULA_SC	24	arm, events	10 / 240		R0016038:Figure 1
AWARD-8	A2	PLACEBO	24	arm, events	0 / 60		R0016038:Figure 1
NCT02465515	A1	PLACEBO	140.89	arm, events	334 / 4,732		registry:outcomes
NCT02465515	A2	ALBI_SC	140.89	arm, events	427 / 4,731		registry:outcomes
NCT01733758	A2+A3	ALBI_SC	52	arm, events	15 / 310	printed_denominator;arms_combined	R0010997:Table 2
NCT01733758	A4	LIRA_SC	52	arm, events	1 / 103	printed_denominator	R0010997:Table 2
LIRA-SWITCH™	A1	LIRA_SC	27	arm, events	13 / 203	count_from_percent	R0025720:Results
LIRA-SWITCH™	A2	SITAGLIPTIN	27	arm, events	5 / 204	count_from_percent	R0025720:Results
DURATION-NEO-2	A1	EXENER_SC	28	arm, events	3 / 182		R0010641:Table 3
DURATION-NEO-2	A2	SITAGLIPTIN	28	arm, events	0 / 122		R0010641:Table 3
DURATION-NEO-2	A3	PLACEBO	28	arm, events	3 / 61		R0010641:Table 3
NCT05514535	A1	SEMA_SC	45	arm, events	10 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	1 / 285		R0015842:Table 2
NCT03985293	A1	PLACEBO	20	arm, events	5 / 66		R0006095:Table 3
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	52 / 346	arms_combined	R0006095:Table 3
NCT06974825	A1+A2+A3	BGM050_SC	20	arm, events	1 / 38	arms_combined	R0015161:Supplement Appendix D.1
NCT06974825	A4	SEMA_SC	20	arm, events	0 / 16		R0015161:Supplement Appendix D.1
NCT06974825	A5	PLACEBO	20	arm, events	0 / 13		R0015161:Supplement Appendix D.1
DUALTM IX	A1	IDEGLIRA_SC	27	arm, events	4 / 210		R0014323:Results
DUALTM IX	A2	INS_GLARGINE	27	arm, events	1 / 210		R0014323:Results
SURPASS-4	A1+A2+A3	TIRZ_SC	108	arm, events	101 / 997	arms_combined	R0007531:Supplement Table S2
SURPASS-4	A4	INS_GLARGINE	108	arm, events	54 / 1,005		R0007531:Supplement Table S2
SUSTAIN	A1+A2	SEMA_SC	30	arm, events	48 / 578	arms_combined	R0014802:Table 3
SUSTAIN	A3	SITAGLIPTIN	30	arm, events	6 / 290		R0014802:Table 3
NCT00360334	A1	EXEN_SC	26	arm, events	7 / 118		R0024925:Table 3
NCT00360334	A2	INS_GLARGINE	26	arm, events	4 / 117		R0024925:Table 3
NCT04552470	A1	PLACEBO	12	arm, events	0 / 9		R0004540:Supplement Table S1
NCT04552470	A2+A3+A4	DANU_PO	12	arm, events	6 / 28	arms_combined	R0004540:Supplement Table S1
NCT01003184	A1	EXENER_SC	26	arm, events	12 / 111		R0027663:Table 2
NCT01003184	A2	INS_DETEMIR	26	arm, events	5 / 111		R0027663:Table 2
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	4 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	0 / 94		R0004355:Table 2
PIONEER 6	A1	SEMA_PO	87	arm, events	184 / 1,591		registry:outcomes
PIONEER 6	A2	PLACEBO	87	arm, events	104 / 1,592		registry:outcomes
AWARD-CHN2	A1+A2	DULA_SC	52	arm, events	17 / 515	arms_combined	R0023722:Figure 1
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	2 / 259		R0023722:Figure 1
NCT00917267	A1	EXENER_SC	26	arm, events	15 / 340	count_from_percent;printed_denominator	R0026895:Results
NCT00917267	A2	EXEN_SC	26	arm, events	35 / 338	count_from_percent;printed_denominator	R0026895:Results
GETGOAL-X	A1	LIXI_SC	24	arm, events	33 / 320		R0022279:Results
GETGOAL-X	A2	EXEN_SC	24	arm, events	41 / 319		R0022279:Results
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	40 / 480	arms_combined	R0025024:Table 2
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	4 / 121		R0025024:Table 2
NCT05486065	A1+A2+A3	SEMA_SC	49	arm, events	29 / 185	arms_combined	R0005510:Table 2
NCT05486065	A4	PLACEBO	49	arm, events	1 / 60		R0005510:Table 2
DUAL™ II China	A1	IDEGLIRA_SC	30	arm, events	2 / 302		R0012135:Results
DUAL™ II China	A2	INS_DEGLUDEC	30	arm, events	2 / 151		R0012135:Results
SURPASS-3	A1+A2+A3	TIRZ_SC	56	arm, events	101 / 1,079	arms_combined	R0015264:Table 2
SURPASS-3	A4	INS_DEGLUDEC	56	arm, events	5 / 365		R0007531:Supplement Table S2
SURPASS-5	A1+A2+A3	TIRZ_SC	44	arm, events	30 / 355	arms_combined	R0007531:Supplement Table S2
SURPASS-5	A4	PLACEBO	44	arm, events	3 / 120		R0007531:Supplement Table S2
NCT00744926	A1	PLACEBO	24	arm, events	4 / 123	printed_denominator	R0025346:Table 1
NCT00744926	A2+A3	TASP_SC	24	arm, events	30 / 245	printed_denominator;arms_combined	R0025346:Table 1
NCT00641056	A1	EXENER_SC	84	arm, events	16 / 233		R0027747:Table 1
NCT00641056	A2	INS_GLARGINE	84	arm, events	4 / 234		R0027747:Table 1
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	8 / 390	arms_combined	R0019663:Table 3
PIONEER 11	A4	PLACEBO	31	arm, events	3 / 131		R0019663:Table 3
NCT01272232	A1	LIRA_SC	68	arm, events	39 / 423		R0026209:Table 7
NCT01272232	A3	PLACEBO	68	arm, events	7 / 212		R0026209:Table 7
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	14 / 264	arms_combined	R0012671:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	1 / 133		R0012671:Table 2
SUSTAIN™ 2	A1+A2	SEMA_SC	56	arm, events	72 / 818	printed_denominator;arms_combined	R0021710:Table 2
SUSTAIN™ 2	A3	SITAGLIPTIN	56	arm, events	12 / 407	printed_denominator	R0021710:Table 2
NCT02229227	A1	ALBI_SC	26	arm, events	12 / 402		registry:outcomes
NCT02229227	A2	INS_LISPRO	26	arm, events	6 / 412		registry:outcomes
LIRAFLAME	A1	LIRA_SC	26	arm, events	8 / 51		R0010519:Results
LIRAFLAME	A2	PLACEBO	26	arm, events	1 / 51		R0010519:Results
SURPASS-SWITCH	A1	TIRZ_SC	44	arm, events	4 / 139		R0008264:Results
SURPASS-SWITCH	A2	DULA_SC	44	arm, events	1 / 143		R0008264:Results
NCT01632163	A1	LIXI_SC	24	arm, events	8 / 224		R0014725:Table 3
NCT01632163	A2	PLACEBO	24	arm, events	4 / 224		R0014725:Table 3
NCT00676338	A1	EXENER_SC	26	arm, events	6 / 248		R0027761:Figure 1
NCT00676338	A2	METFORMIN	26	arm, events	6 / 246		R0027761:Figure 1
NCT00676338	A3	PIOGLITAZONE	26	arm, events	5 / 163		R0027761:Figure 1
NCT00676338	A4	SITAGLIPTIN	26	arm, events	1 / 163		R0027761:Figure 1
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.43	arm, events	4 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.43	arm, events	20 / 160		R0015751:Table 3
NCT03550378	A1	COTA_SC	8.43	arm, events	2 / 21		R0019218:Results
NCT03550378	A2	PLACEBO	8.43	arm, events	1 / 20		R0019218:Results
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	36 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	5 / 102		R0007136:Table 2
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	14 / 205	arms_combined	R0014736:Table 2
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	2 / 103		R0014736:Table 2
NCT02690883	A1	INS_LISPRO	24	arm, events	6 / 46		R0011086:Results
NCT02690883	A2	EXEN_SC	24	arm, events	5 / 46		R0011086:Results
Lixilan-L-CN	A1	IGLARLIXI_SC	30	arm, events	4 / 212		R0014540:Table 3
Lixilan-L-CN	A2	INS_GLARGINE	30	arm, events	3 / 214		R0014540:Table 3
NCT04998032	A1	EFSUBA_SC	24	arm, events	2 / 171		R0006975:Figure 1
NCT04998032	A2	PLACEBO	24	arm, events	2 / 173		R0006975:Figure 1
NCT03311724	A1	PLACEBO	12	arm, events	1 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	12	arm, events	2 / 85	arms_combined	R0010282:Table 2
PIONEER 3	A1+A2+A3	SEMA_PO	78	arm, events	107 / 1,397	count_from_percent;arms_combined	R0024670:Abstract
PIONEER 3	A4	SITAGLIPTIN	78	arm, events	24 / 467	count_from_percent	R0024670:Abstract
GETGOAL-MONO	A1	PLACEBO	12	arm, events	1 / 122	printed_denominator	R0022843:Table 2
GETGOAL-MONO	A2+A3	LIXI_SC	12	arm, events	8 / 239	arms_combined	R0022843:Table 2
S002858	A1	LIXI_SC	24	arm, events	3 / 51		R0001573:Supplement Table S1
S002858	A2	PLACEBO	24	arm, events	2 / 50		R0001573:Supplement Table S1
S002904	A1	LIRAGL_SC	24	arm, events	7 / 60		R0003210:Results
S002904	A2	LIRA_SC	24	arm, events	2 / 60		R0003210:Results
S002947	A1+A2+A3	ECNO_SC	25	arm, events	1 / 109	arms_combined	R0006482:Table 2
S002947	A4	PLACEBO	25	arm, events	0 / 36		R0006482:Table 2
S002951	A1	PEGLOX_SC	16	arm, events	5 / 104		R0007588:Table 3
S002951	A2	METFORMIN	16	arm, events	3 / 52		R0007588:Table 3
S002969	A1	LIRA_SC	26	arm, events	5 / 13		R0010852:Results
S002969	A2	PLACEBO	26	arm, events	0 / 14		R0010852:Table 3
S002984	A1	PEGLOX_SC	24	arm, events	1 / 39		R0011969:Results
S002984	A2	INS_GLARGINE	24	arm, events	1 / 39		R0011969:Results
S003009	A1	PEGLOX_SC	24	arm, events	1 / 44		R0011381:Table 4
S003009	A2	DAPAGLIFLOZIN	24	arm, events	1 / 44		R0011381:Table 4
S003041	A1	LINAGLIPTIN	2	arm, events	0 / 18		R0020035:Supplement Figure S1
S003041	A2	LIRA_SC	2	arm, events	0 / 17		R0020035:Supplement Figure S1
S003047	A1+A2	LIXI_SC	6	arm, events	2 / 80	printed_denominator;arms_combined	R0016337:Table 3
S003047	A3	PLACEBO	6	arm, events	1 / 40	printed_denominator	R0016337:Table 3
S003071	A1	LIRA_SC	24	arm, events	0 / 50		R0023696:Results
S003071	A2	SITAGLIPTIN	24	arm, events	1 / 49		R0023696:Results
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results
S003108	A1+A3	LIRA_SC	24	arm, events	0 / 60	arms_combined	R0025278:Figure 1
S003108	A2	METFORMIN	24	arm, events	0 / 30		R0025278:Figure 1
S003108	A4	LIRAMETF_SC	24	arm, events	0 / 30		R0025278:Figure 1
S003426	A1	SEMA_SC	24	arm, events	3 / 38		R0040396:Abstract
S003426	A2	TIRZ_SC	24	arm, events	2 / 41		R0040396:Abstract
S003442	A1	DULA_SC	24	arm, events	0 / 48	printed_denominator	R0016372:Results
S003442	A2	LIRA_SC	24	arm, events	0 / 48	printed_denominator	R0016372:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab